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Currently there is no sufficient bridge to lung transplant for patients with end-
stage lung disease. Thoracic artificial lungs (TAL) are being developed for this purpose. 
TALs are attached to the pulmonary circulation, and thus their blood flow is provided by 
the right ventricle (RV). Current TALs possess blood flow impedances greater than the 
natural lungs, resulting in low cardiac output (CO) when implanted in series with the 
natural lung or in parallel under exercise conditions. In series attachment is desired so 
that the natural lung will still filter blood and perform its non-respiratory functions.  
However, in parallel attachment may allow for high flow applications. The goal of this 
research was to design a device with minimal impedance which does not cause a 
significant decrease in CO when attached in series, or in parallel with cases of high 
device flows, such as exercise.  This was done both through the examination of geometry 




A new compliant TAL (cTAL) was designed, prototyped and tested both in vitro 
and in vivo. First, computational fluid dynamics (CFD) and fluid-structure interaction 
(FSI) modeling were used to investigate inlet and outlet expansion and contraction 
angles, θ, of 15°, 45°, and 90° in both hard-shell TALs and cTALs. The 45° model was 
chosen for the cTAL prototype and tested in vitro and in vivo in the acute setting, 
attached both in parallel and in series with the native lungs.  
The combination of a gradual entrance and exit to the device, as well as a 
compliant housing resulted in a device impedance of 0.5 mmHg/(L/min), much lower 
than the native lungs and all other existing TAL designs. The fiber bundle of the cTAL 
provided excellent gas transfer, with a rated flow well above 7 L/min. The cTAL 
developed with this research is capable of lower flow PA-PA attachment, with up to 50% 
of CO to the cTAL. PA-LA attachment of the cTAL will allow for excellent exercise 





Chapter 1  
Introduction 
 
Motivations and Objectives 
The only long term solution for chronic lung disease is lung transplantation; 
however, organ donation is limited and cannot supply the demand. Currently there is no 
sufficient bridge to lung transplant for patients with end-stage lung disease. Available 
devices and support methods are unable to provide complete respiratory support for these 
patients without causing blood damage or further deterioration of the disease state, often 
resulting in multiple organ failure. Thoracic artificial lungs (TAL) are being developed 
without blood pumps for these patients in order to minimize blood damage, coagulation, 
and inflammation. TALs are attached to the pulmonary circulation, and thus their blood 
flow is driven by the right ventricle (RV). 
Several groups, including our lab, have developed a TAL for long-term 
respiratory support which is either placed in parallel or in series with the natural lungs. In 
vivo testing has revealed weaknesses in all existing TAL device designs, including high 
device impedance which can cause performance problems in both attachment 
configurations. Current TALs possess blood flow impedances greater than the natural 
lungs, resulting in low cardiac output (CO) when implanted in series with the natural 




blood and perform its non-respiratory functions. Recent studies in our lab with the MC3 
Biolung which simulate rest and exercise conditions have shown advantages in placing 
the device in parallel. CO was maintained with high flows to the TAL in rest and 
ambulatory conditions, albeit with significantly elevated right ventricular pressure. The 
goal of this research was to design a device with minimal impedance which does not 
cause a significant decrease in CO when attached in series, or in parallel with cases of 
high device flows, such as exercise.  This was done both through the examination of 
geometry changes to the TAL housing and through the use of a compliant housing 
material. 
A new compliant TAL (cTAL) was designed, prototyped and tested both in vitro 
and in vivo. First, computational fluid dynamics (CFD) and fluid-structure interaction 
(FSI) modeling were used to examine different housing geometries in both hard-shell 
TALs and cTALs. Second, in vitro hemodynamic testing was conducted with the TAL 
and cTAL models. Gas transfer performance of the cTAL was also assessed in vitro. 
Finally, the optimal cTAL prototype was tested in vivo in the acute setting, attached both 
in parallel and in series with the native lungs.  
 
Lung Disease and Transplantation 
Lung disease is the third leading cause of death in the United States, responsible 
for 1 in 6 deaths. These death rates are currently increasing, and more than 35 million 
Americans have chronic lung diseases [1]. There are four categories of chronic lung 
disease which lead to end-stage lung disease: obstructive lung disease (asthma, chronic 




disease), infectious lung disease (cystic fibrosis), and pulmonary vascular disease 
(pulmonary arterial hypertension). There are many therapies used to treat these diseases, 
but the only permanent cure is lung transplantation. COPD, idiopathic pulmonary fibrosis 
(IPF), cystic fibrosis, emphysema, and idiopathic pulmonary arterial hypertension (IPAH) 
are the most common diseases that lead to lung transplantation [2,3]. However, there is a 
shortage of donor lungs available for transplant in these patients. In the U.S. in 2009, 
there were 1,660 lung transplantations but 2,280 new patients registered on the waiting 
list [3]. 
  
Respiratory Support Options 
When a patient’s lungs are unable to adequately maintain blood O2 or CO2 
requirements, respiratory support is required. There are several different respiratory 
support techniques and devices, some of which are still under investigation. One of the 
most widely used is mechanical ventilation. 
Mechanical ventilation can be used for breathing support in both acute and 





The mechanical ventilator applies pressure to a patient’s airway through an endotracheal 
or tracheostomy tube, causing gas to flow into the lungs until the ventilator breath is 
terminated.  Airway pressure drops to a set baseline expiratory pressure, causing elastic 
recoil of the chest wall and passive exhalation. Acute respiratory distress syndrome 
(ARDS) is respiratory failure due to lung inflammation and increased vascular 
permeability caused by direct or indirect lung injury. Current treatment of ARDS 
involves mechanical ventilation with positive end expiratory pressure (PEEP). The goal 
of mechanical ventilation is to support a patient’s breathing while allowing his/her lungs 
to recover.  However, ventilation can also cause direct damage to the lungs. 
Complications from ARDS include infections, pneumothorax, and lung scarring, all 
 
Figure 1.1: Illustration of a patient on a mechanical ventilator.  





which can be caused by ventilation [4]. Deaths from ARDS usually results from multiple 
system organ failure (MSOF). Research suggests mechanical ventilation triggers the 
release of inflammatory mediators into the lungs and circulation, a mechanism termed 
biotrauma, possibly causing MSOF [5]. Advances in ventilator strategies have reduced 
ventilator-induced lung injury and mortality in ARDS patients [6]. Mechanical 
ventilation could also be used for a short period to support respiratory function in chronic 
lung disease patients. However, in 2011 the International Society for Heart and Lung 
Transplantation reported ventilation prior to transplant as a significant risk factor for both 
1-year and 5-year mortality in adult lung transplant recipients [2].  Thus, mechanical 
ventilation is a contraindication for lung transplantation. 
There are several alternatives to mechanical ventilation which provide either 
partial or total respiratory support. Extracorporeal membrane oxygenation (ECMO, also 
known as extracorporeal life support) is used to treat cardiac or respiratory failure 
providing respiratory support (V-V ECMO) or respiratory and cardiac support (V-A 
ECMO) for days or weeks. ECMO is prolonged extracorporeal (outside the body) 
cardiopulmonary support through vascular cannulation. In V-V ECMO, blood is taken 
from the venous system, routed through the circuit where it is oxygenated, and then 
returned to the venous system (jugular vein in and out, or jugular vein to right femoral 
vein). For V-A ECMO, blood is taken from the venous system and returned to the arterial 
system (carotid artery and vein, femoral artery and vein, or aorta and right atrium). The 
ECMO circuit is large, consisting of: a blood pump, a servoregulator, an oxygenator, a 





ECMO is used more frequently in neonates in whom survival rates are higher than in 
adults [7]. The ECMO circuit has a large priming volume and utilizes a pump which 
causes continuous mechanical stress resulting in blood cell damage [8]. Like mechanical 
ventilation, ECMO has been considered to be a contraindication to lung transplant with a 
low 1-year survival rate of 45% [9,10]. Several retrospective studies report the clinical 
use of ECMO to successfully bridge patients to lung transplant; however, these studies 
have varying post-transplant survival rates that are dependent on initial patient selection 
[11,12]. Initial examination of the use of ECMO in awake, non-intubated patients (no 
mechanical ventilation support) shows improved 1-year survival rates and a more 
 
Figure 1.2: Standard V-A ECMO circuit. Blood is pumped from the right atrium, 
through a membrane oxygenator and heat exchanger, and then returned to the 
arterial circulation. Heparin and other fluids are given through this circuit. ECMO 




promising bridging technique [13]. Advances in pump and oxygenator technology and 
using ECMO as an alternative to mechanical ventilation have improved outcomes and 
shown the possibility of using ECMO as a bridge to lung transplantation. However, it is 
still an invasive, complex technique requiring a team of specialists and blood 
transfusions. Because of its complexity and number of components, there are many 
avenues for complications. Complication rates are reported by the ELSO registry, broken 
down by type and mode of support [14]. Some of the most common are: oxygenator 
failure (8-17%), blood clots in the system components (9-15%), cannula problems (5-
15%), and bleeding at the surgical site (6-33%) or cannula site (7-21%). 
Arterio-venous carbon dioxide removal (AVCO2R) is another respiratory support 
technique which uses a simple arterio-venous (AV) shunt (i.e. femoral artery to vein) 





CO2 is transferred across the membrane of the gas exchanger, while nearly all O2 diffuses 
across the native lungs. Blood flow is driven by the patient’s arterial blood pressure, 
eliminating the need for a pump.  Device flows up to 25% of CO are achieved while up to 
96% of CO2 produced is removed; allowing reduction of ventilator support to 16% of 
baseline minute ventilation [15]. This technique has been used clinically to treat patients 
with ARDS and pneumonia [16-18]. In these studies, hypercapnia was reversed, allowing 
for less aggressive ventilator settings. The disadvantage to this therapy is low O2 transfer 
due to oxygenated blood entering the device and, to a lesser extent, the low blood flows. 
 
Figure 1.3: Arterio-venous CO2 removal circuit. Blood flows from a cannula inserted 
in the femoral artery, through a membrane oxygenator where gas exchange occurs, 
and then back to the patient through a cannula inserted in the femoral vein.  




Therefore, AVCO2R benefits patients with severe hypercapnia and ARDS, but not 
patients with hypoxemia [8]. More recently, AVCO2R has been utilized for a bridge to 
lung transplant [11, 19]; however, oxygenation was limited due to blood flow restrictions 
and thus could only be used in patients with severe hypercapnia and only moderate 
hypoxia. Also, only patients with adequate mean arterial pressure (>70 mmHg) and 
sufficient cardiac output could undergo this procedure. Thus, this technique is not 
adequate as a bridge to lung transplant. 
The only clinical device for AVCO2R is the Novalung iLA (Figure 1.4).  
 
This device has also recently been used as a bridge to transplant, connected between the 
pulmonary artery and left atrium. This has been initially used in patients with end-stage 
pulmonary hypertension [20-23]. Patients were supported anywhere from 8-62 days until 
transplantation. During that time, Schmid et al reported that pulmonary artery pressure 
decreased down to 45-60 mmHg; however, this still constitutes rather severe pulmonary 
hypertension. The device was exchanged, on average, every 15 days due to fibrin 
deposition which decreased gas exchange. In all these studies, device flow ranged from 
 





1.8-3.0 L/min during support. This attachment mode allows the patient to be mobile; 
however, with increasing physical activity CO increases. Schmid et al reported that as 
their patient resumed physical activity, increased CO led to more flow through native 
lung since flow to device couldn’t be increased. Thus, a larger fraction of unsaturated 
blood arrived at the left atrium. The resistance of the Novalung is approximately 5-6 
mmHg/(L/min) at blood flows of 2-2.5 L/min [17,18,24]. The Novalung was not intended 
for PA-LA use when constructed. A device with lower resistance that allows for higher 
flows would provide total respiratory support and allow patients to be ambulatory and 
even exercise while awaiting lung transplant. 
Intravascular oxygenators, small devices implanted in the vena cava, have been 
studied for more than 20 years and offer advantages over ECMO which include a small 
blood contact surface, decreased operation time, and a priming volume of zero. However, 
clinical trials with one such device, the IVOX, showed inadequate gas exchange, 
providing O2 transfer of only 20-30% of whole body requirements [25,26]. This device 
consists of a bundle of hollow fibers which are joined together at their ends. The IVOX is 
inserted, through the femoral vein, in a compact state and the fibers are then unfurled in 
the vena cava (Figure 1.5(a)). O2 flows through the center lumen of the device and then 
through the fibers (Figure 1.5(b)). Gas exchange takes place between the lumen of fibers 





Recent advances in device design have been made to increase blood flow through the 




Figure 1.5: (a) Picture of the IVOX in its unfurled state and (b) cross-sectional 
schematic of the IVOX, showing the gas flow path through the device. Kallis et al. Eur 
J of Cardiothorac Surg 7(4): 206-210, 1993. 
 
Figure 1.6: Highly integrated intravascular membrane oxygenator (HIMOX) utilizing 
a series of disc-shaped fiber bundles along a core and an axial blood pump. Cattaneo 




Gas exchange was also increased by decreasing fiber porosity, however this lead to a 
higher pressure drop resulting in bundle deformation and a blood shunt around the device 
[27]. Another method of increasing blood velocities and enhancing gas exchange is the 
utilization of a pulsating balloon in the center of a bundle of fibers (Figure 1.7).  
 
The fiber bundle is constrained around an un-inflated balloon, making the device smaller 
than the vessel lumen size and allowing blood to shunt past the device to reduce flow 
resistance. By rapidly pulsating the balloon, blood flows through the fiber bundle and 
passes by the fibers as relatively higher velocities. This intravenous respiratory assist 
catheter, also known as the Hattler catheter, has been shown to enhance gas exchange 
over the IVOX, providing O2 transfer rates of 175-305 mL/min/m
2, depending on balloon 
pulsation rate [28]. Investigators predict that a 0.5m2 device could provide 50% of total 
O2 requirements; however, the devices tested in this study had a surface area of about 
 
Figure 1.7: Schematic of the intravenous respiratory assist catheter, consisting of a 





0.23m2. Since intravascular oxygenators are small, bundle surface area must be 
maximized to maximize gas transfer. However, this results in higher blood flow 
resistance, reducing venous return to the heart. Thus, despite the above design 
improvements, these devices cannot provide total respiratory support and are not a 
sufficient bridge to lung transplant. 
Artificial lung systems which utilize a pump or rotating fiber bundle to drive 
blood flow have been developed by several groups [29-31]. These rotating fiber bundle 
devices use centrifugal force and high shear stress to mix the blood and enhance gas 
exchange (Figure 1.8).  
 
 
Figure 1.8: Schematic of the paracorporeal assist lung (PRAL) which utilizes a 





The disadvantage of these devices is the high shear rates which cause platelet activation 
and hemolysis. Previous research demonstrated that platelet activation is a function of 
shear stress magnitude and duration of application and that shear-induced platelet 
activation occurs only above a threshold of 12-15 dyne/cm2 [32-34]. Svitek et al 
estimated duration of support for their device to be 7-10 days. They reported high levels 
of hemolysis at the higher rotating rates and calculated the maximum shear stress of their 
device due to rotation to be 80 dynes/cm2. This is well above the threshold for shear-
induced platelet activation. Recent testing with a new artificial pump-lung (APL) device 
has shown little to no hemolysis during 30-day in vivo testing [35]. In this device, blood 
is drawn from the patient (i.e. right atrium or femoral vein) into the pump chamber. 
Blood is propelled through a diffuser section, driven by a magnetically levitated rotating 
centrifugal pump impeller, and then enters the fiber bundle in the radial direction. Gas 
exchange occurs as blood passes through the bundle, until it finally exits the device and 





This device has the advantage of being compact, with a small priming volume; however 
it is only designed to provide blood flows of 3.5 L/min. Additional testing may be 
required to examine device performance in ambulatory or exercising patients and patients 
with pulmonary hypertension. 
 
Thoracic Artificial Lung Development 
The devices and techniques described above are either not suitable as a bridge to 
lung transplant or too early in their development. Such a device must be durable, simple 
to operate, provide total respiratory support, minimize blood damage and activation, and 
have low resistance. This device must also allow patients to be awake and ambulatory 
while awaiting lung transplant. 
 
Figure 1.9: Cross-sectional view of the artificial pump lung (APL) showing the blood 




Thoracic artificial lungs (TAL) are being developed to meet these requirements. 
TALs do not use a pump, but rather are attached to the pulmonary circulation with the 
right ventricle (RV) driving blood flow. Elimination of the need for a blood pump greatly 
reduces blood damage, coagulation, and inflammation. The patient’s own cardiac output 
(CO) controls the device, making it simple to operate. Depending upon patient 
requirements, the TAL can be attached in parallel or in series with the natural lungs 
(Figure 1.10).  
 
During in parallel attachment blood flow is routed from the pulmonary artery (PA), 
through the TAL and then returned to the left atrium (LA). This configuration reduces 
impedance of the TAL and natural lung system; however, less blood flows through the 
TAL. Therefore, some blood flow travels to the systemic circulation without being 
filtered by the natural lungs, allowing embolic material to reach the major organs.  
During in series attachment, blood is routed from the proximal PA through the TAL and 
then back to the distal PA where the blood then flows through the native lungs and finally 
back to the LA. This configuration eliminates the risk of systemic emboli by allowing the 




lung to perform its filtration and non-respiratory functions. In addition, the entire cardiac 
output can flow through the TAL, allowing for complete gas exchange. Studies on TAL 
attachment mode have shown parallel TAL attachment to decrease pulmonary system 
impedance and increase CO, while in series attachment increases pulmonary system 
impedance and decreases CO [36]. 
The MC3 Biolung (MC3, Ann Arbor, MI) has been tested in our lab for up to 30 
days in sheep [37,38]. In this device, venous blood flows in through the center of the 
device, radially across the cylindrical fiber bundle, and exits through the duel outlets. Gas 
flows through the fibers while blood flows over the fibers, with gas exchange occurring 
through the fiber walls (Figure 1.11). 
 
The Biolung was attached in the PA-LA configuration without any coating to enhance 
biocompatibility. In the 30-day study, the average device use was 9.5 days with 51% of 
CO flowing to the TAL. Average device resistance over 30 days was 2.6 mmHg/(L/min) 
at 2 L/min of device flow. The Biolung is now moving toward clinical trial. Recent 
studies with the MC3 Biolung which simulate rest and exercise conditions have also 
 




shown advantages in placing the device in parallel [39]. CO was maintained with high 
flows to the TAL in rest and ambulatory conditions. At exercise conditions, CO 
decreased with increasing flow to the TAL. Further decreases in device impedance are 
necessary for increased exercise tolerance. 
Despite promising Biolung results, in series attachment would still be desired if it 
did not induce RV dysfunction. However, current TALs possess blood flow impedances 
greater than the natural lungs, resulting in low CO when implanted in series with the 
natural lung [40]. Increased pulmonary system impedance in the in series configuration is 
caused by the additive impedance of the TAL and natural lung. This induces low CO via 
increased RV oxygen demand, decreased RV oxygen supply, decreased contractile 
function, and pulmonic valve dysfunction [41-43]. Patients with respiratory failure, 
specifically those suffering from PH, may not be able to tolerate any additional 
impedance from the TAL. In PH the PA pressure is high, causing increased work for the 
right heart and often results in RV failure. Therefore, in series attachment of the TAL will 
further increase pulmonary system impedance and the right heart workload, possibly 
hastening RV failure.  
Impedance is the opposition to pulsatile blood flow and is determined from a 
relationship between the time-varying components of pressure and flow. Fourier 
transforms are used to convert pressure, P(t), and flow, Q(t), waveforms in the time 



















where P0 and Q0 are the average pressure and flow magnitudes. The sinusoid at each 
harmonic, n, has its own magnitude (Pn or Qn), frequency (ω), and phase shift (φ). 
Harmonic frequencies are equal to integer multiples of the heart rate. Impedance is 





Z   
The zeroth and first harmonic impedance moduli (Z0 and Z1), are most physically 
relevant as the opposition to steady flow and flow at a frequency equal to the heart rate, 
respectively. Since CO is affected mostly by Z0 and Z1, e these are our focus. Impedance 
is a function of TAL resistance, compliance, and inertance, with impedance increasing 
with increasing resistance and inertance and decreasing with increasing compliance. An 
inlet compliance chamber (Figure 1.12) has been shown to reduce Z1 by nearly 80% and 
to a lesser extent, Z0 in both in vitro and in vivo studies [40,44,45].  
 
 
Figure 1.12: Biolung with a polyurethane compliance chamber attached to its inlet. 




McGillicuddy et al minimized Z0 and Z1 in vitro at compliances greater than 1 and 5 
ml/mmHg, respectively. By reducing device impedance, the work of the RV is also 
reduced by dampening the pulsatile flow and creating a more steady flow throughout the 
cardiac cycle. Despite reducing device impedance, overall system impedance (Z0=5.75 
mmHg/(L/min) and Z1=2.41 mmHg/(L/min)) was still greater than that of the natural 
lungs (baseline Z0=2.87 mmHg/(L/min) and Z1=0.96 mmHg/(L/min)) during in series 
attachment, causing a decrease in CO. Sato et al suggest that most of the RV dysfunction 
is due to an increase in the zeroth harmonic impedance, Z0, due to its effects on average 
system pressures, and a smaller decrease in CO is caused by the first harmonic 
impedance modulus, Z1, due to its effect on systolic pressures. Kuo et al confirmed that 
Z0 is the key determinant of RV output in their study examining the effect of pulmonary 
system impedance on CO [46]. For every 1 mmHg/(L/min) increase in Z0 there is an 
approximate 3.65% decrease in CO. Likewise, for every 1 mmHg/(L/min) increase in Z1 
there is a 0.08Z0% decrease in CO. Akay et al performed a similar study, examining the 
relationship between pulmonary system impedance on CO in sheep with pulmonary 
hypertension [47]. Results again indicated that Z0 had a significant effect on percent 
change in CO, %ΔCO, and found that: %ΔCO = -7.45*ΔZ0. Therefore, the foremost goal 
of TAL design should be to reduce Z0, with a secondary requirement to limit increases in 
Z1. Sato et al concluded that the resistance of the compliance chamber, device or 
anastomoses must be reduced to improve CO [40]. The compliance chamber design has a 
limited volume and a large expansion and contraction which significantly adds to the 






An entire compliant device, having a housing made out of a flexible material, can 
accommodate a larger change in volume with less stretching. This was examined through 
a compliant TAL (cTAL) design which utilized a compliant Biospan (segmented 
polyurethane) housing (Figure 1.13).  
 
Initial studies with this device showed a significant dampening of the flow pulse; 
however the device had excessive inlet and outlet resistances [48]. The inlet and outlet 
regions had abrupt expansions and contractions, leading to minor losses due to flow 
separation. Recirculations are created in these regions, decreasing the efficiency of the 
system and leading to higher device impedance. Uneven blood flow can negatively affect 
biocompatibility, activating blood clotting factors and causing clots to form in low flow 
areas. We propose the incorporation of more gradual expansions and contractions in the 
cTAL to reduce losses, improve flow and reduce resistance in the inlet and outlet housing 
 
Figure 1.13: Original cTAL prototype, consisting of a compliant Biospan housing and 




regions. This will be accomplished by decreasing the inlet and outlet expansion angle, θ, 
of the inlet and outlet housing manifolds (Figure 1.14). 
 
Decreasing θ results in the elongation of the entrance and exit to the cTAL, creating more 
gradual expansions and contractions (Figure 1.15). 
 
 
Summary of the Study 
The goal of this work was to design a low impedance cTAL which prevents large 
decreases in CO when used in series with the natural lungs and has excellent exercise 
tolerance when used in a PA-LA configuration. This was accomplished using CFD and in 
 
Figure 1.14: Inlet and outlet expansion angle, θ, of the cTAL inlet and outlet 
housing manifolds. 




vitro models to determine ideal housing geometry. Hard-shell TALs were considered first 
to determine the effects of housing geometry alone on impedance. FSI analysis was then 
used to assess a compliant housing’s ability to further reduce impedance in different 
cTAL models. The ideal cTAL was prototyped and underwent hemodynamic and gas 
transfer testing in vitro. Finally, cTALs were tested in vivo, both in parallel and in series, 
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Chapter 2  
Thoracic Artificial Lung Housing Design 
 
Introduction 
Current TALs and cTALs possess blood flow impedances greater than the natural 
lungs, resulting in abnormal pulmonary hemodynamics when implanted in series with the 
natural lung or in parallel with high flows to the TAL [1,2]. Previous studies have shown 
the majority of cTAL impedance was due to excessive inlet/outlet impedances [3]. It was 
theorized that the abrupt expansions and contractions at the inlet and outlet regions cause 
flow recirculation that, in turn, leads to higher device impedance. If this is the case, more 
gradual expansions and contractions could improve flow patterns and reduce device 
impedance. Device design also influences flow uniformity within the cTAL. It is essential 
to have even flow throughout the fiber bundle and housing in order to have efficient gas 
transfer and eliminate any low flow areas where blood clots can form. Thus, device 
design is essential to optimize both the impedance and biocompatibility of the cTAL.  
The effect of housing geometry on cTAL impedance will be explored in Chapter 
3 using fluid-structure interaction (FSI) modeling. However, the influence of housing 
geometry alone will first be considered in simplified, rigid-housing TAL designs. In this 
chapter, the inlet and outlet expansion angle, θ, of the TAL was adjusted, and flow 




First, computational fluid dynamics (CFD) was used to examine the effects of different 
housing designs on device flow patterns and impedance. Flow patterns are important in 
predicting gas transfer performance and biocompatibility and cannot be easily visualized 




Computational Fluid Dynamics Studies 
The effects of θ on TAL blood flow patterns and impedance were evaluated using 
designs with θ= 15°, 45° and 90° (Figure 2.1).  
SolidWorks (Dassault Systèmes SolidWorks Corp, Concord, MA) computer-aided design 
(CAD) software was used to create each housing model, which was then imported into 
the ADINA (ADINA R&D Inc., Watertown, MA) computational fluid dynamics (CFD) 
software program (Figure 2.2).  
 







In these models, blood flows through the inlet, expands into the inlet manifold, flows 
through the fiber bundle at the center of the device, then travels through the outlet 
manifold and exits through the device outlet. The inlet/outlet diameter, height and width 
of each TAL model are 0.016 m, 0.103 m and 0.102 m, respectively. The fiber bundle 
length, path length (the distance blood must flow through the bundle), and frontal area 
(the cross-sectional area perpendicular to blood flow through the bundle) are 0.140 m, 
0.038 m, and 0.016 m2, respectively, for each model. The 15°, 45°, and 90° models have 
a total length of 0.350 m, 0.229 m, and 0.191 m. Since the inlet/outlet tube diameter and 
the housing body geometry is fixed, the length of the expansion/contraction section 
increases as θ decreases (see Figure 2.1). 
 
CFD: Problem Formulation 
Program assumptions included a transient solution with incompressible flow. 
Turbulent flow was assumed to occur in the inlet and outlet sections.  The average 
Reynolds numbers in the inlet and outlet sections at flow rates of 2, 4, and 6 L/min are 
920, 1800, and 2760, respectively. Peak Reynolds numbers at these same flows are 3000, 
6100, and 9200, respectively. The material properties of the rigid housing and fiber 
 




bundle, along with the fluid characteristics of blood were defined in the program. Blood 
viscosity and density were set to 0.003 Pa s (3.0 cP) and 1040 kg/m3. The fiber bundle 
region was modeled as porous media with fluid density, porosity, permeability, and fluid 
viscosity defined as 1040 kg/m3, 0.75, 2.81x10-9 m2, and 0.003 Pa s (3.0 cP), 









where Q is blood flow rate, μ is viscosity, L is the fiber bundle path length, A is the fiber 
bundle frontal area, and ΔP is the pressure drop across the fiber bundle. The hollow fiber 
bundle was modeled using a porous media theory to determine flow characteristics within 
the bundle [4-7]. 
The fluid motion outside the fiber bundle is governed by the Navier-Stokes 
equations with constant density and viscosity, together with the continuity equation as 
follows: 




  (2) 
0 V  (3) 
where f is the blood density, f is the blood viscosity, P is the pressure and V is the 
velocity vector. 
 
CFD: Boundary Conditions 
A symmetry condition was utilized in ADINA, allowing the model to be cut in 




perpendicular to the symmetry face. A no-slip wall boundary condition was also applied 
to the inlet and outlet housings, while a slip wall boundary condition was applied to the 
bundle walls. The momentum equation used in the porous media model does not contain 
any second order derivatives, thus viscous effects are negligible and a slip wall condition 
is used. The initial pressure condition was set to 10 mmHg. A time dependent velocity 
was applied to the inlet face and a constant pressure of 10 mmHg was applied to the 
outlet face to simulate left atrial pressure.  
Pulsatile blood flow through the device was simulated in ADINA at average flow 
rates (Q) of 2, 4, and 6 L/min and heart rates (HR) of 80 and 100 beats/min (Figure 2.3). 
 
 
Figure 2.3: TAL inlet flow waveform for CFD and in vitro studies at 4 L/min, 100 




 This inlet flow waveform, Qi, is a simulated RV output with a pulsatility of 3.75. 
Pulsatility is defined as (maximum flow rate – minimum flow rate)/average flow rate. 

















































where Vs is the stroke volume defined as: 
HR
Q
Vs   (5) 
tes is the end-systolic time defined as: 
    263 1044.4108.143.0 HRHRtes    (6) 




  (7) 
and A is the flow pulse scaling factor used to scale flows to match the CO. The duration 
of regurgitation is assumed to be 0.04s. In reality, device inflow is less pulsatile since the 
TAL is attached to the pulmonary artery (PA) which dampens the pulse. Thus, this 
waveform represents the most extreme case the device would encounter. A more typical 
inlet waveform with a lower pulsatility of 2 was also investigated (Figure 2.3) [3]. This 
waveform is created by sending the previously discussed RV output waveform through a 





CFD: Numerical Scheme 
A finite element formulation based on the Galerkin method was utilized to solve 
the governing equations. In this method, the governing equations (equations 2 and 3) are 
converted into discretized equations which can be solved numerically. In order to achieve 
converged and accurate results, a value of 10-5 was set for the relative error. The mesh 
size and time step of the model were varied until a converged solution was reached. The 
convergence criterion was set at ≤1.5% difference in impedance between models of 
different time step or mesh size. A variable grid size system was employed in the present 
study to capture the rapid changes in the velocity and pressure variables occurring in 
specific regions. A finer mesh was implemented at the inlet and outlet faces in order to 
accurately determine pressure and flow data. Also, a finer mesh along the inlet and outlet 
cylindrical region was required for convergence. In the end, the mesh size was 3 mm for 
the bodies, 0.25 mm for the inlet and outlet sections, and 1.0 mm for the inlet and outlet 
faces. A time step of 0.005 s was used. 
 
CFD: Data Analysis 
The simulation was run for three consecutive heart beats to achieve a converged 
periodic solution. Inlet and outlet pressure and overall flow rate data from the final beat 
were obtained from the program for presentation and analysis. To determine the 
impedance moduli, Fourier transforms were used to convert the inlet pressure and flow in 

















n tQQtQ   

 (9) 
where P0 and Q0 are the average pressure and flow magnitudes, Pn and Qn are the 
pressure and flow magnitudes at the nth harmonic, ωn is the frequency at the nth 
harmonic, t is time, and ϕn is the phase shift at the nth harmonic. Impedance moduli at the 









  (10) 
where Pi and Po are the inlet and outlet device pressures. Values of Z0 and Z1 were 
calculated and used to asses TAL impedance. Pressure and flow data were also obtained 





  (11) 
where PTB is the average pressure across the top fiber bundle face, PBB is the average 
pressure across the bottom fiber bundle face, and Q is average flow through the bundle. 
 In order to separately investigate the viscous pressure drop, the average pressure 
drop due to an expansion or contraction, ΔPec, was calculated: 


































1   (12) 
where ρ is the density of blood, Q(t) is the time-dependent blood flow through the device 
at Q=4 L/min and HR=100 beats/min, A1 is the cross-sectional area of the inlet/outlet, and 
A2 is the cross-sectional area of the fiber bundle. Since our goal was to understand the 




change this, this calculation was done at one representative flow condition for both the 
45° and 90° models. Equation 12 was numerically integrated using the trapezoidal rule. 










, , (14) 
where ΔP is the pressure drop for the inlet, bundle, or outlet section, and Q=4 L/min. No 
adjustment is necessary for the fiber bundle resistance, as it does not include an 
expansion or contraction. The percentage of total device resistance was then calculated 
for the inlet, bundle and outlet sections. 
 Velocity band plots were created in ADINA to investigate flow uniformity in the 
housing and fiber bundle of each model. Plots were created on a cross section along the 
y-axis (top down view) for several sections in the housing and fiber bundle of the device. 
In these plots, color is used to indicate velocity magnitude where red represents the 
highest velocity in the plot range and blue represents a velocity of 0 m/s. These plots 
were created at peak systole and end-diastole in the cardiac cycle for two different 
velocity ranges. Velocity vector plots were also created to investigate areas of 
recirculation in each housing model. In these plots, color and the size of the vectors are 
used to indicate velocity magnitude where red represents the maximum velocity in the 





In Vitro Testing 
Experimental tests were run on two TAL rigid housing models to validate the 
computer results. The models tested had θ = 45° and 90°. To create the fiber bundle, 
woven mats of polypropylene fibers with a fiber diameter of 200 μm were wound into 
compact bundles with porosity, path length, and frontal area of 0.75, 0.038 m, and 0.016 
m2, respectively. The bundle was potted with WC7-53 (BJB Enterprises Inc., Tustin, 
CA), a two part polyurethane, into an acrylic box. Three sets of housings for each θ were 
machined from PVC blocks and then clamped above and below a fiber bundle. The 
blocks were carved out in the center, so that they are the negative of the housing shown in 
Figure 2.1. In vitro testing was conducted with a circuit consisting of a pulsatile pump 
(Harvard Apparatus, Holliston, MA), TAL model, and reservoir.  The entire circuit was 
primed with a 3.0 cP glycerol solution (Figure 2.4).  
 
Pressure transducers (see Figure 2.4) were connected to six luers on the model in 
order to monitor device pressure at the inlet (P1), outlet (P2), top of the bundle (P3 and 
P5), and bottom of the bundle (P4 and P6). A blood flow probe was placed before the 
 
Figure 2.4: In vitro test circuit consisting of a pulsatile pump, TAL model, and 
reservoir filled with 3.0 cP glycerol solution. Six pressure lines were connected to the 
model at the inlet (P1), outlet (P2), top of the bundle (P3 and P5), and bottom of the 




device inlet to monitor flow rate. Using the pulsatile pump, testing was conducted for 
HR= 80 and 100 beats/min and Q= 2, 4, and 6 L/min. Average pulsatilities for these 
flows were 3.33. A representative inlet flow rate waveform at a HR=100 beats/min, Q=4 
L/min, and pulsatility = 3.33 is shown in Figure 2.3.  In addition, the 45° model was 
tested at a pulsatility of 1.7 with HR=100 beats/min and Q=4 L/min to examine the 
effects of pulsatility on device impedance. To reduce the pulsatility, a compliance 
chamber [2] with C = 0.5 was placed in the circuit before the device inlet. The BIOPAC 
MP150 data acquisition system (Biopac Systems, Inc., Goleta, CA) was used to acquire 
pressure and flow data. Fourier transforms were then performed on this data to calculate 




















Viscous resistance was calculated at Q=4 L/min and HR=100 beats/min for the inlet, 
bundle and outlet section of each model in a similar fashion as the CFD simulation. 
Stroke volume, SV, was calculated as Q/HR. Correlations between Z0 and SV and between 
Z1 and Q were created. 
Comparisons between in vitro Z0 and Z1 were performed with SPSS (SPSS, 
Chicago, IL) using a mixed model with housing prototype number as the subject variable, 






CFD: Rigid Housing TAL 
Figure 2.5 displays TAL Z0 CFD results for varying stroke volumes at a pulsatility 
of 3.75.  
 
Device Z0 increases linearly as SV increases, as well as increasing with larger θ. At Q=4 
L/min and HR=100 beats/min (SV=0.04 L), Z0 was 0.47, 0.61, and 0.79 mmHg/(L/min) 
for the 15°, 45°, and 90° devices, respectively. The correlations relating Z0 to SV were: 
Z0 = 1.82SV + 0.41, R
2=97.7%, for θ=15°  (16) 
Z0 = 6.17SV + 0.39, R
2=97.4%, for θ=45°  (17) 
Z0 = 10.7SV + 0.36, R
2=98.7%, for θ=90°  (18) 
 
Figure 2.5: Effect of θ on TAL Z0 for varying stroke volumes: comparison between in 





Figure 2.6 displays Z1 CFD results at varying heart rates and flow rates at a 
pulsatility of 3.75.  
The values of Z1 increase linearly with flow rate for the 15° model; however, they remain 
more uniform at each flow rate for the 45° and 90° models. Z1 is larger at HR=100 
beats/min for all three models.  Lastly, Z1 was similar between the 45° and 90° models 
but noticeably greater for the 15° model. At Q=4 L/min and HR=100 beats/min, Z1 was 
0.67, 0.40, and 0.35 mmHg/(L/min) for the 15°, 45°, and 90° models, respectively. 
Device Z0 was reduced slightly under more typical in vivo conditions with a lower 
inlet flow pulsatility; however, Z1 was not affected. At Q=4 L/min and HR=100 
beats/min, the 45° model Z0 was 0.53 mmHg/(L/min) at a pulsatility of 2 vs. 0.61 
mmHg/(L/min) at a pulsatility of 3.75. The 45° model Z1 was 0.41 mmHg/(L/min) at a 
pulsatility of 2 vs. 0.40 mmHg/(L/min) at a pulsatility of 3.75. Lastly, fiber bundle 
 





resistance for all models was 0.31 mmHg/(L/min). The majority of device resistance 
came from the fiber bundle and inlet housing sections in each design. Table 2.1 lists the 
viscous resistances in the inlet, bundle, and outlet sections for the 45° and 90° models at 
an example condition of Q=4 L/min and HR=100 beats/min. 
 
Table 2.1: Viscous Resistance in the inlet, bundle and outlet sections for the 45° and 90° 
in vitro and CFD models at Q=4 L/min and HR=100 beats/min. 
Resistance  In Vitro, 45° CFD, 45° In Vitro 90° CFD 90° 
Inlet, 
mmHg/(L/min)  
0.25 ± 0.06 0.21 0.26 ± 0.09 0.31 
Inlet,  
% of Total 
36.2 ± 10.5% 34.2% 32.2 ± 10.9% 39.4% 
Bundle, 
mmHg/(L/min) 
0.31 ± 0.11 0.31 0.28 ± 0.09 0.31 
Bundle,  
% of Total 
43.5 ± 14.1% 49.4% 35.1 ± 12.9% 38.7% 
Outlet, 
mmHg/(L/min) 
0.14 ± 0.16 0.10 0.26 ± 0.12 0.17 
Outlet, 
% of Total 
20.3 ± 19.2% 16.4% 32.7 ± 12.4% 22.0% 
Total, 
mmHg/(L/min) 
0.70 ± 0.14 0.62 0.81 ± 0.10 0.79 
 
 
Band plots taken at peak systole for Q = 4 L/min, HR = 100 beats/min, and 
pulsatility = 3.75 and 2 are shown in Figure 2.7(a) along a section in the device inlet 
region for two different plot ranges. These plots indicate areas of little to no flow at the 
distal end of the 15° and 45° device, as indicated by the blue color. Also, the wider range 
(0-0.014 m/s) plots indicate that flow is more even in the inlet housing of the 15° model. 
A smaller pulsatility of 2 seems to result in slightly more even flow, but with large low 




the 15° and 45° model with slightly lower flow near the front of the device in the 90° 
model (Figure 2.7(b)). 
 
During diastole (Figure 2.8), no more flow is entering the device and velocities are lower 
overall; however, velocites are higher in the 45° and 90° models due to recirculation. The 
extent of this recirculation is more easily visualized with velocity vector plots. 
 
Figure 2.7: Velocity band plots for the 15° and 90° CFD TAL models at a pulsatility 
of 3.75 and the 45° model at a pulsatility of 3.75 and 2. Shown at peak systole in the 





 Velocity vector plots of the inlet housing region, taken at the beginning of diastole 
(t=1.58s) for Q = 4 L/min, HR = 100 beats/min, and pulsatility = 3.75, are shown in 
Figure 2.9. 
 
Figure 2.8: Velocity band plots for the 15° and 90° CFD TAL models at a pulsatility 
of 3.75 and the 45° model at a pulsatility of 3.75 and 2. Shown at end-diastole for two 




A magnified view of the major recirculation regions (indicated in Figure 2.9(a)) are 
shown in Figure 2.9(b). Large vortices occur near the distal end of the 90° device while 
smaller recirculation regions occur in the proximal end of the 15° and 45° devices. In the 
90° model at peak systole (Figure 2.10), large vortices occur in the proximal end, as well 
as smaller one at the distal end of the device.  
 
Figure 2.9: (a) Velocity vector plots for the 15°, 45°, and 90° CFD TAL models at the 
beginning of diastole (t=1.58s) in the inlet housing region. (b) Magnified view of the 






The large vortices in this device travel from the proximal end to the distal end of the 
model (with flow) as time in the cardiac cycle progresses (Figure 2.11). The 15° and 45° 
models also have vortices occurring throughout the cardiac cycle; however, these are 
smaller and mainly occur in the proximal end of the device. Overall, a lower pulsatility of 
2 results in less recirculation in the housing; however, like the 15° model, there is a large 
low flow region at the distal end of the device (Figure 2.11). 
 
Figure 2.10: (a) Velocity vector plot for the 90° TAL model during peak systole 
(t=1.32s) in the inlet housing region. Magnified view of the major recirculation areas 






Velocity vector plots taken in the housing outlet (Figure 2.12) showed small regions of 
recirculation in the outlet tube (Figure 2.12b) and downstream end of the housing (Figure 
2.12c) during diastole only. However, the velocities in these vortices were very small 
compared to those in the housing inlet. 
Figure 2.11: Velocity vector plots for the 15° and 90° CFD TAL models at a 
pulsatility of 3.75 and the 45° model at a pulsatility of 3.75 and 2. Shown at end-






In Vitro Testing 
The effect of θ on TAL in vitro Z0 and Z1 is shown in Figures 2.5 and 2.13, 
respectively, for an average pulsatility of 3.3. Z0 varied significantly with SV (p<10
-19) 
and θ (p<0.01). The 45° model had a significantly lower Z0 than the 90° model overall. 
At Q=4 L/min and HR=100 beats/min (SV=0.04 L), Z0 = 0.69±0.13 and 0.79±0.10 
mmHg/(L/min) for the 45° and 90° models, respectively. The correlations relating in 
vitro Z0 to SV (in L) were: 
Z0 = 8.889SV + 0.297, R
2=91.1%, for θ=45° (19) 
Z0 = 9.084SV + 0.396, R
2=93.0%, for θ=90° (20) 
 
Figure 2.12: (a) Velocity vector plot for the 45° TAL model at the beginning of 
diastole (t=1.58s) in the outlet housing region. Magnified view of the outlet tube (b) 





Values for Z1 varied significantly with HR (p<0.01), Q (p<10
-30), and θ (p<10-6).  
The effect of HR was very small compared to Q and θ, but indicated that Z1 increased 
with HR. The 90° model had significantly lower Z1 than the 45° model. At Q=4 L/min 
and HR=100 beats/min, Z1 = 1.23±0.27 and 0.91±0.0.13 mmHg/(L/min) for the 45° and 
90° models, respectively. The correlations relating in vitro Z1 for each θ and HR are: 
Z1 = 0.096Q + 0.737, R
2=99.4%, for θ=45°, HR=80 beats/min (21) 
Z1 = 0.118Q + 0.789, R
2=98.6%, for θ=45°, HR=100 beats/min (22) 
Z1 = 0.165Q + 0.222, R
2=99.99%, for θ=90°, HR=80 beats/min (23) 
Z1 = 0.189Q + 0.192, R
2=99.4%, for θ=90°, HR=100 beats/min (24) 
 
Figure 2.13: Effect of θ on TAL Z1: comparison between in vitro and CFD results for 




Overall, in vitro Z1 were larger and showed a stronger dependence on θ and Q than CFD 
results. These larger Z1 were due to larger peak pressures in vitro, even though average 
pressure drops were similar between the CFD and in vitro studies.  
Average fiber bundle resistance for all models was 0.29 mmHg/(L/min), nearly 
identical to CFD results.  In the 45° model, the majority of device resistance came from 
the fiber bundle and inlet housing sections. However, in the 90° model, the relative 
contribution to total device resistance was almost identical for each section (Table 2.1). 
 Lastly, at a lower pulsatility of 1.7 with Q=4 L/min and HR=100 beats/min 
(SV=0.04 L), the 45° model had Z0=0.65 mmHg/(L/min) and Z1=1.29 mmHg/(L/min).  
The Z0 and Z1 are 0.69 and 1.23 mmHg/(L/min) at the same conditions with pulsatility 
equal to 3.2.  Therefore, as predicted in the CFD study, pulsatility does not greatly 
influence impedance in vitro. 
 
Discussion 
The impedances of all the TAL designs tested in this study are significantly lower 
than previous designs. Experiments with the MC3 Biolung (MC3, Ann Arbor, MI) [9] and 
a cTAL [3] report Z0=1.8 and 1.9 mmHg/(L/min), respectively at 3.0 cP glycerol flows of 
Q=4 L/min and HR=100 beats/min. At the same flow and heart rate, the 45° and 90° 
model in the current study had Z0=0.69±0.13 and 0.79±0.10 mmHg/(L/min). These 
values are also significantly lower than the impedance of the natural lung: Z0=1.25 
mmHg/(L/min). Z1 in the healthy, natural lung is 0.49 mmHg/(L/min) [10]
 compared to 




The effect of SV and θ on Z0 was very similar in the CFD and in vitro results.  
However, CFD modeling predicted lower Z1 values overall with a minimal effect of θ and 
Q. The Z1 is more heavily influenced by differences in flow rate patterns and thus has a 
higher variability than Z0 during in vitro testing. Overall, the Z1 values measured for both 
models are small and unlikely to influence device function in vivo [11].  
The 45° and 90° devices tested in this study had a 62 and 56% lower in vitro Z0 
than previous designs. This decrease should improve RV function during attachment in 
vivo. The ultimate effect of lower impedance on cardiac function depends on attachment 
mode.  The most likely clinical application for these devices is attachment in parallel with 
the natural lung in a PA to left atrium (LA) configuration.  If attached in parallel with the 
natural lung, lower TAL impedance may allow patients to more easily exercise during 
device attachment. Akay et al attached the MC3 Biolung in parallel with the pulmonary 
circulation in sheep with chronic pulmonary hypertension and varied the percentage of 
CO through the device under simulated rest, ambulatory, and exercise conditions [1]. At 
ambulatory and resting conditions, CO was maintained as the percentage of CO to the 
device increased. At exercise conditions, CO decreased with increasing flow to the TAL 
up to 23 ± 5% at 90% flow diverted through the TAL. TAL impedance increases and the 
natural lung impedance decreases with increasing blood flow. Thus, during exercise with 
elevated CO, a higher percentage of CO may travel through the native lungs reducing 
respiratory support when attached in parallel. Further decreases in device impedance may 
allow for complete exercise tolerance and optimal device performance. 
If attached in series with the natural lung, from the proximal to distal PA, lower 




Previous studies by Kim et al, Kuo et al, and Akay et al developed relationships between 
acute increases in Z0 and Z1 and the resultant percent decrease in CO [11-13].  These 
studies can be used to predict the improvement in CO using these devices vs. previous 
designs.  In the devices tested here, Z1 values are small in all devices, regardless of 
design, and should not have a measureable effect on CO [11]. Values of Z0 should, on the 
other hand, contribute to lowering CO. The increase in pulmonary system impedance 
(ΔZ) due to the TAL impedance (ZTAL) can be calculated with the equation: 
ΔZ = ZTAL f  (25) 
where f is the fraction of flow to the TAL. If we assume CO to be 6 L/min and allow 4 
L/min to travel through the TAL then f=2/3. Using the 45° model in vitro data at Q=4 
L/min, HR=100 beats/min, pulsatility=1.7, and adding 0.87 mmHg/(min) for the 
anastomoses resistance [13], ΔZ0 and ΔZ1 are 1.01 and 0.86 mmHg/(L/min), respectively. 
The Kim, Kuo, and Akay relationships predict a 4.1, 13, and 7.6% decrease in CO, 
respectively. For the previous TAL designs, we would predict a decrease of 15, 19, and 
13%. Based on these predictions, the 45° model should cause a small decrease in CO. If 
we average the Kim, Kuo, and Akay data, f = 0.75 will give a 10% reduction in CO. This 
decrease may be tolerable in patients with normal pulmonary vascular resistance or mild 
pulmonary hypertension and normal right ventricular function.  It would not in patients 
with marked pulmonary hypertension and right ventricular dysfunction. If necessary, f 
could be reduced to further decrease the drop in CO. 
The CFD model also provided important information on how device design 
affects flow patterns in both the housing and fiber bundle. Changes in Z0 can be explained 




patterns were more pronounced in the housing inlet. The fiber bundle acted to evenly 
distribute blood flow, resulting in more even blood flow in the housing outlet and only 
small, low-velocity, recirculations. Recirculation occurred in the inlet of all three models; 
however, recirculations decreased as θ decreased. The 90° housing inlet had several 
regions of large vortices throughout the cardiac cycle, while the 15° and 45° models had 
smaller areas of recirculation.  
Device design also affected flow uniformity in the housing inlet and fiber bundle. 
Flow uniformity is essential to the short and long-term function of the device. Regions of 
little or no flow offer little gas exchange when they occur in the fiber bundle and, worse 
yet,  can lead to a buildup of activated clotting factors  and clot formation when they 
occur at any of the device artificial surfaces. The 15° and 45° models had areas of little to 
no flow near the distal end of the inlet. These areas were larger in the 15° model where 
flow was barely reaching past the middle of the housing body. The stasis regions in the 
back of the device can never completely be eliminated for the angled housings, but 
further geometry changes may help, such as a shorter distance between the inlet and the 
back and tapered corners in the back.  Tapered corners are easily incorporated during the 
production process when the fiber bundle is “potted” in urethane to separate the blood 
and gas phases of the device. 
 Ultimately, the optimal device must have a combination of low impedance, even 
flow, and reasonable size for use by an ambulatory patient.  While the 15° model had 
smaller recirculation regions and low impedance, it had a large stasis region near the 
distal end of the device. Also, the long inlet and outlet length of the 15° model may make 




of low impedance, better flow patterns, and relatively compact size. The low impedance 
of the 45° model should allow for a minimal, acute decrease in CO at rest if implanted in 
series with the natural lung and increased exercise tolerance when compared to previous 
TAL designs if attached in parallel with high flows to the TAL. These results will be 
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Chapter 3  
Compliant Thoracic Artificial Lung Design and Testing 
 
Introduction 
CFD and in vitro studies with a rigid-housing TAL showed that device impedance 
was reduced as the inlet and outlet expansion angle, θ, decreased. The optimum 
combination of low impedance and good flow patterns was achieved with the 45° 
housing model. Now we will confirm these results and investigate whether additional 
reductions in TAL impedance may be achieved by using a compliant housing material. 
Unlike a hard-shell TAL, the compliant housing can expand to accommodate the large 
changes in blood volume seen during a heartbeat. This dampens the flow pulse, creating a 
more steady flow through the cardiac cycle. 
This study aimed to reduce TAL impedance using a compliant housing material in 
conjunction with more gradual inlet and outlet geometries, as explored in Chapter 2. In 
this compliant thoracic artificial lung (cTAL), blood flows through the inlet and into the 
compliant inlet manifold (Figure 2.1). The housing expands, accommodating the stroke 
volume without a large pressure increase. Blood then flows through the fiber bundle 
where gas exchange occurs, through the bottom housing manifold and finally exits 
through the outlet. The effect of inlet and outlet expansion angle, θ, on cTAL impedance 




analysis was necessary to examine the interaction between fluid forces and housing 
deformation. The optimal cTAL design was determined from FSI results, prototyped, and 
tested in vitro to assess impedance and gas transfer performance. 
 
Methods 
Fluid Structure Interaction Analysis 
SolidWorks was used to create cTAL models with varying housing geometries 
using θ= 15°, 45°, and 90° (Figures 2.1 and 2.2). The inlet/outlet diameter, height, and 
width of each cTAL model are 0.016 m, 0.103 m, and 0.102 m, respectively. The fiber 
bundle length, path length, and frontal area are 0.127 m, 0.038 m, and 0.013 m2, 
respectively, for each model. The 15°, 45°, and 90° models have a total length of 0.338, 
0.221 m, and 0.178 m. These models were then imported into ADINA. For FSI analysis, 
separate structure and fluid models were created, coupled and then run together. The fluid 
model consisted of all regions that fluid passed through while the structure model 
consisted of the Biospan housing.  
 
FSI: Problem Formulation 
Program assumptions included a transient solution with incompressible flow. At a 
flow of 3 L/min, the Reynolds number during peak flow was 4150 in the inlet section, 
170 coming out of the bundle into the outlet section, and 3300 exiting the device. Due to 
limitations in the CFD software, we could not apply turbulent flow to the fiber bundle 




independently, while carrying boundary conditions from one section to the next. Two 
such solutions were attempted: i) running each section independently, with turbulence in 
the inlet and outlet sections and laminar flow in the bundle (as done for TAL models in 
Chapter 2), and ii) running the inlet section as turbulent and remainder of the model as 
laminar. The former gave unrealistic flow patterns and dampening (detailed further in 
discussion). The latter gave us the most quantitatively accurate and physically realistic 
results possible and is thus presented here.  
In the fluid model, the properties of the fiber bundle and the fluid characteristics 
of blood were defined as described in the TAL CFD study (Chapter 2). A slip wall 
boundary condition was applied to the bundle walls while a FSI condition was used in the 
inlet and outlet regions. A pressure of 770 mmHg (absolute pressure) was applied at the 
outlet and also used for the initial pressure condition. A time dependent velocity was 
applied to the inlet face using the same pulsatile flow waveform (as described in Chapter 
2) with average flow rates, Q, of 3 and 5 L/min and a heart rate, HR, of 100 beats/min.  
The structure model consisted of the compliant, Biospan (DSM PTG, Berkeley, 
CA) housing, with a thickness of 0.51 mm, forming the inlet and outlet sections of the 
model. Biospan was defined as an elastic isotropic material with a Young’s modulus of 
6.21 MPa, Poisson’s ratio of 0.40, and density of 1030 kg/m3. FSI boundary conditions 
were applied to each face and shell elements were used with a face thickness of 0.51 mm. 
The edges bordering the fiber bundle were fixed in all directions, along with the inlet and 
outlet edge to prevent translation of the model in space. Symmetry plane edges were 




the model by applying a pressure load of 760 mmHg to the exterior faces of the structure 
model. 
The governing equations used for the problem formulation in the fluid domain are 
the continuity and Navier-Stokes equations: 








where u is the fluid velocity vector, f  is the fluid density, ug is the moving coordinate 
velocity, Bff  is the body force per unit volume,  guu   is the relative velocity of the 
fluid with respect to the moving coordinate velocity, and f is the fluid stress tensor.  
The governing equation for the solid domain of the FSI model is the 
elastodynamics equation: 
B
ssss fσd   (2) 
where s  is the wall density, s is the solid Cauchy stress tensor, 
B
sf is the externally 
applied body force vector at time t and sd represents the local acceleration of the solid 
region ( guds   ).  
The boundary conditions at the interface between the fluid domain and the solid 

















where d, , n are the displacement vector, stress tensor, and normal vector, respectively. 





FSI: Numerical Scheme 
A finite element formulation based on the Galerkin method (described in Chapter 
2) was utilized to solve the governing equations. Direct computing of two-way fluid-
structure coupling was used. Convergence criteria were set at ≤ 1.5% difference in 
impedance between models of different time step or mesh size. The final mesh size was 3 
mm for the bodies, 0.25 mm for the inlet and outlet sections, and 1.0 mm for the inlet and 
outlet faces. A time step of 0.001 s was used. 
 
FSI: Data Analysis 
The fluid and structure models were run simultaneously with FSI analysis for four 
consecutive heart beats to achieve a converged, periodic solution. Inlet and outlet 
pressure data, along with flow, from the final beat were obtained from the program. Z0 
and Z1 were calculated and used to assess cTAL impedance. Pressure and flow data was 
also obtained from the top and bottom fiber bundle faces to determine bundle resistance. 
Average maximum housing displacement, Davg, was also calculated, from absolute 
magnitude values, over the last heartbeat for the inlet and outlet manifold of each model 
at each flow condition. 
ADINA was also used to create velocity vector plots, at the beginning of diastole 
in the cardiac cycle, to investigate areas of recirculation in each housing model. In these 
plots, color and the size of the vectors are used to indicate velocity magnitude where red 
represents the maximum velocity in the plot range and blue represents a velocity of 0 m/s. 




bundle of each model. Plots were created on a cross section along the y-axis (top down 
view) for cross sections at the entrance to the fiber bundle from the inlet section and in 
the middle of the fiber bundle. In these plots, color denotes velocity magnitude with red 
representing the highest velocity in the plot range and blue representing a velocity of 0 
m/s. A plot range of 0-0.0081 m/s was created at peak systole in the cardiac cycle. 
 
Compliant Thoracic Artificial Lung 
The cTAL model with θ= 45° was prototyped for in vitro testing (Figure 3.1).  
 
The compliant housing was created by dipping a mold into Biospan (DSM PTG, 
Berkeley, CA), a polyurethane polymer, until a housing thickness of 0.51 mm was 
achieved. The device also consisted of a bundle of polypropylene hollow fibers which 
had a fiber diameter, porosity, path length, frontal area, and surface area of 210 μm, 0.75, 
0.038 m, 0.013 m2, and 2.4 m2, respectively. Device compliance was determined using 
previously reported methods [1]. Fluid volume was slowly added to the device, while 
 




pressure was recorded and compliance was calculated as ΔV/ΔP, until an added fluid 
volume of 560 mL was reached. 
 
In Vitro Testing: Hemodynamics 
  In vitro testing was conducted in a circuit consisting of a pulsatile pump (Harvard 
Apparatus, Holliston, MA), cTAL (n = 4), and reservoir filled with 3.0 cP glycerol 
solution (Figure 3.2a). The reservoir was raised 12.6 cm above the cTAL outlet, resulting 
in a constant device outlet pressure of 10 mmHg. Fluid-coupled pressure transducers 
(Abbott Critical Care Systems, Chicago, IL) measured pressure at the cTAL inlet (Pi) and 
outlet (Po). A flow probe (14PXL, Transonic Systems Inc, Ithaca, NY) measured the flow 





The pulsatile pump created six flow conditions: heart rates (HR) of 80 and 100 beats/min 
and flow rates (Q) of 2, 4, and 6 L/min. At each condition, a data set of QcTAL, Pi, and Po 
was digitally acquired for 15 seconds at a sampling frequency of 250 Hz through a 
BIOPAC data acquisition system (BIOPAC, Goleta, CA). Fourier transforms were then 
performed on this data to calculate Z0 and Z1. Stroke volume, SV, was calculated as 
Q/HR, and linear regressions were performed between Z0 and Z1 and SV. 
 
 
Figure 3.2: (a) In vitro testing circuit for resistance study consisting of pulsatile pump, 
cTAL, and reservoir filled with 3.0 cP glycerol solution. Two pressure lines were 
connected to the model at the inlet (P1) and outlet (P2). (b) Gas transfer testing circuit 
consisting of a reservoir filled with bovine blood, roller pump, deoxygenator 




In Vitro Testing: Gas Transfer 
 The gas transfer performance of four cTALs was tested in a recirculation circuit 
consisting of bovine blood (Figure 3.2b). Blood was pumped by a roller pump (Baxter 
Century, Baxter, Deerfield, IL) from the recirculation reservoir, through a deoxygenator 
(Capiox Rx 25, Terumo Cardiovascular Systems, Ann Arbor, MI) and returned to the 
reservoir in order to bring the blood to venous conditions according to AAMI protocols 
[2]. The sweep gas used to condition the blood consisted of varying levels of O2, N2, and 
CO2. Once the blood was conditioned, blood flow was routed from the pump to the 
cTAL. Blood was pumped through the cTAL at flow rates of 3, 5, and 7 L/min, and 
oxygen flow was set at a gas to blood flow ratio of two. 
 Blood samples were taken from the cTAL inlet and outlet and analyzed to 
determine PO2, PCO2, pH, SO2, and hemoglobin concentration. The O2 and CO2 transfer 
rates were calculated with the following standard formulas: 
VO2 = Qb(k(po-pi)+1.34chb(so-si)) (4) 
VCO2 = QgcCO2 (5) 
where Qb is the blood flow rate, k is the solubility of oxygen in blood, po is outlet PO2, pi 
is inlet PO2, chb is the hemoglobin concentration, so is the outlet fractional 
oxyhemoglobin saturation, si is the inlet fractional oxyhemoglobin saturation, Qg is the 






Fluid Structure Interaction Analysis 
The compliant housing of the cTAL caused dampening of device outlet flow. Inlet 
and outlet flow waveforms for Q=3 L/min are shown in Figure 3.3. 
 
Figure 3.4 displays FSI results with cTAL Z0 and Z1 on the y axis and SV on the x axis.  
 
Figure 3.3: cTAL inlet and outlet flow waveforms for the FSI models at 3 L/min 
and 100 beats/min, showing outlet flow dampening. Representative cTAL inlet 





For the 15° and 45° models, Z0 increases minimally as SV increases. In the 90° model, 
however, Z0 increased 13% from SV=0.03 to 0.05 L. At SV=0.03 L, Z0 was 0.50, 0.69, 
and 0.92 mmHg/(L/min) for the 15°, 45°, and 90° devices, respectively. Z1 increases with 
increasing θ and at SV=0.03 L, Z1 is 0.16, 0.50, and 0.93 mmHg/(L/min) for the 15°, 45°, 
and 90° models, respectively. Velocity vector plots in the inlet region (Figure 3.5) depict 
recirculation regions in the inlet that increase in size and velocity with θ, explaining the 
effect of θ on Z0. 
 






Velocity band plots taken at cross sections in the inlet region at the entrance to the 
fiber bundle (Figure 3.6a) and the middle of the fiber bundle (Figure 3.6b) are shown in 
Figure 3.6.  
 
Figure 3.5: (a) Velocity vector plots for the 15°, 45°, and 90° cTAL models at the 
beginning of diastole (t=2.14s) in the inlet housing region. (b) Magnified view of the 





Figure 3.6a shows areas of low flow in the distal end of the housing in the 15° and 45° 
models. At the entrance to the fiber bundle, flow is mostly uniform at the proximal end of 
all models, except for a small spot in the 45° and 90° models.  Figure 3.6b shows uniform 
flow in the fiber bundle, with very small velocity differences between the proximal and 
distal ends. Velocity in the bundle at peak systole in the 90° model is slightly higher than 
the other models. This is due to less dampening of the flow pulse in the inlet region of the 
90° model, causing more blood to enter the fiber bundle during systole (see below). 
Figure 3.7 shows the flow waveforms entering the fiber bundle for each model. Peak flow 
is highest for the 90° model, while flow grows more even across the cardiac cycle with 
decreasing θ. 
 
Figure 3.6: Velocity band plots for the 15°, 45°, and 90° cTAL models at peak systole 







Table 3.1: Maximum housing displacement in one heart beat, Dmax, and average 
maximum housing displacement over one heart beat, Davg, for the inlet and outlet housing 








15° 3 1.97 1.82 
15° 5 2.29 2.04 
45° 3 1.8 1.66 
45° 5 2.08 1.86 
90° 3 1.64 1.51 
90° 5 1.95 1.73 
 
 





Flow dampening occurs due to the housing expanding and contracting with the 
flow pulse. The average maximum housing displacement over one heart beat, Davg, for 
the inlet and outlet housing sections is given in Table 3.1 for each model and flow rate.  
With increasing Q, Davg increases for both housing sections. Housing displacement is 
larger in the inlet section than in the outlet section. Displacement occurs more gradually 
over the flow pulse for smaller θ, causing Davg to be largest in the 15° model. 
 
In Vitro Testing: Hemodynamics 
The cTAL had two different compliance values, which were dependent on 
pressure. At low pressures, the device was still filling with fluid and the housing hadn’t 
begun stretching, resulting in a large compliance. At higher pressures, the housing of the 
cTAL stretched to accommodate the increase in fluid, and the compliance was smaller. 
Figure 3.8 shows the compliance curve for a typical device. Average cTAL compliance 
was 93.9 ± 8.75 mL/mmHg for internal pressure < 5 mmHg and 5.21 ± 0.57 mL/mmHg 





In vitro Z0 and Z1 data for varying SV are displayed in Figure 3.9. 
 
Figure 3.8: In vitro compliance curve for a typical device. The slope of the volume vs. 
pressure linear curves at high pressure and low pressure is equal to the compliance in 





As SV increases, Z0 decreases slightly from 0.53 ± 0.08 mmHg/(L/min) at SV=0.02 L to 
0.41 ± 0.14 mmHg/(L/min) at SV=0.075 L. The correlation relating Z0 to SV was: Z0 = -
2.691SV + 0.615, R2=65%. The value of Z1 increases with SV, with a correlation of Z1 = 
9.472SV + 0.485, R2=75%. In vitro, Z1 values are higher than the FSI models predicted, 
while experimental Z0 values are slightly lower.  
 
In Vitro Testing: Gas Transfer 
 Gas transfer performance is shown in Table 3.2.  
 
 





Table 3.2: cTAL gas transfer performance: outlet PO2, outlet SO2, VO2 and VCO2 for 
varying blood flow rates. 






VO2 (mL/min) VCO2 
(mL/min) 
3 436.0 ± 15.9 99.9 ± 0.02 196.6 ± 13.4 330.0 ± 73.2 
5 360.9 ± 54.4 99.9 ± 0.04 307.6 ± 18.0 417.5 ± 91.8 
7 242.8 ± 48.9 99.7 ± 0.14 395.4 ± 42.9 500.5 ± 35.0 
 
 
The outlet PO2 decreases with blood flow rate but remains above 240 mmHg at all 
conditions. Similarly, SO2 remains above 99.5%.  Lastly, VO2 and VCO2 increase 
linearly with increasing blood flow rate. 
 
Discussion 
FSI impedance and flow patterns were used to choose the optimal model for 
prototyping. As θ decreased, impedance decreased. At Q= 3 L/min and HR= 100 
beats/min, Z0 values for the 15°, 45°, and 90° models were 0.51, 0.69, and 0.92 
mmHg/(L/min), respectively. Z1 values were low, under 1 mmHg/(L/min), for all three 
models. For the range of Z0 values found here, an increase in Z1 of 12-24 mmHg/(L/min) 
is necessary in order to decrease CO by 1% [3]. Thus, the Z1 differences found in this 
study are inconsequential, would have no significant effect on cardiac function, and thus 
have no bearing on device selection. 
Based on these results alone, θ = 15° would appear to be the ideal model.  




reach the back end of the manifold, creating a large low flow region at the distal end of 
the device. This low flow region could lead to reduced gas transfer performance and clot 
formation over time. The 45° device had a smaller, low flow region at the distal end. The 
90° model possesses a higher velocity inlet jet that reaches the back end of the device, 
leading to largely uniform flow. Flow through the bundle was mostly uniform in all 
models, with slightly higher velocities at the proximal end. While flow was more 
spatially uniform with higher θ, flow was also less temporally uniform due to lower 
dampening of the flow pulse. Low flow during diastole could also lead to stasis and clot 
formation.  
The 15° model has low impedance and more even flow patterns throughout the 
cardiac cycle but poor flow at the distal end of the device. Moreover, the 15° model is 
excessively long, giving it a large priming volume and making it impractical for 
paracorporeal use. The 90° model has good flow uniformity at the distal end of the device 
but a period of low flow during systole and higher impedance. Thus, the 45° model was 
chosen for prototyping and in vitro testing due to its combination of low impedance, good 
flow patterns, and ease of manufacture.  
In vitro testing demonstrated similar, yet lower values for Z0 than FSI modeling.  
The FSI model was unable to completely mirror the experimental conditions. Due to 
limitations in the CFD software, we were required to split up the model and run the inlet 
section as turbulent and remainder of the model as laminar. In the TAL CFD models 
(Chapter 2) we were able to run both the inlet and outlet sections as turbulent, giving 
results that matched in vitro impedance values much more closely. However, when 




housing section. This gave more quantitatively accurate results for Z0, but unrealistic flow 
patterns. Our final FSI flow assumptions gave us relatively good accuracy for both; 
however, being able to apply turbulent flow uniformly throughout the model may have 
resulted in a more accurate CFD model, resulting in lower Z0 values. Regardless of the 
quantitative results, qualitative results were similar and the 45° model was chosen as the 
optimal design. 
Like the rigid-housing results, the cTAL impedance found with this design is 
much lower than all previous TAL designs and, for that matter, than a healthy native lung 
itself.  Previous experiments examining the impedance of the MC3 Biolung (MC3, Ann 
Arbor, MI) [4] and an early cTAL [1] reported Z0=1.8 and 1.9 mmHg/(L/min), 
respectively at Q=4 L/min and HR=100 beats/min. Studies with the latter device 
suggested the majority of device resistance was from the inlet and outlet regions. The low 
resistance in the cTAL in the current study is a function of three things: a gradual low 
resistance inlet, a low resistance fiber bundle, and a compliant housing. The cTAL’s fiber 
bundle has a resistance of approximately 0.3 mmHg/(L/min), making the combined 
resistance of the inlet and outlet sections around 0.2 mmHg/(L/min).  
The compliant housing of the cTAL served to further lower resistance vs. 





The housing of the cTAL prototype provided a large compliance of 5.21 ± 0.57 
mL/mmHg under high pressure (> 5 mmHg). This compliance allowed the housing to 
expand, accommodating a larger volume of blood during systole and dampening the flow 
pulse. As the housing expands, fluid enters a larger area and the velocity of the fluid 
decreases. Minor losses are reduced and less recirculation occurs, lowering Z0. 
Comparison of cTAL vector plots with those in the hard shell housing TAL described in 
Chapter 2 confirmed that recirculation regions are smaller and have lower velocity in the 
cTAL. This resulted in lower impedances compared to the rigid housing TAL. At 4 L/min 
and 100 beats/min, Z0 was 0.53 ± 0.06 mmHg/(L/min) and Z1 was 0.86 ± 0.08 
mmHg/(L/min) in the cTAL with θ = 45°. In the same device with a rigid housing, 
 
Figure 3.10: Comparison of in vitro Z0 for the hard shell TAL (Chapter 2) and 




Z0=0.69 and Z1=1.22 mmHg/(L/min) [5]. Moreover, unlike TALs with rigid housings, Z0 
decreased slightly with increasing SV in the cTAL (Figure 3.10).  At SV=0.075, Z0 for the 
cTAL and TAL were 0.41 ± 0.14 and 0.94 ± 0.09 mmHg/(L/min), respectively. Thus, at 
higher flow rates, such as those experienced during exercise, there is a larger advantage 
to using the cTAL. 
The lower impedance of the cTAL has implications for use in vivo in both PA-PA 
and PA-LA attachment modes. PA-LA attachment would be advantageous in patients 
with pulmonary hypertension. Since the device has an impedance much lower than the 
natural lungs, blood would flow preferentially through the cTAL. This would allow 
significant unloading of the right ventricle and return PA pressures to normal. One can 
predict how much the cTAL would lower PA pressures by using the simple formula: 
PPA=CO*R+PLA, where PPA is the PA pressure, CO is cardiac output, R is the resistance, 
and PLA is the left atrial pressure. Assuming PVR = 4 mmHg/(L/min), PLA = 6 mmHg, and 
a cTAL resistance of 1.4 mmHg/(L/min) for the TAL plus anastomoses (adding 0.87 
mmHg/(L/min) for the anastomoses) [6], the resulting system resistance with the cTAL 
attached in parallel would be 1.0 mmHg/(L/min). Assuming CO=6 L/min, PPA decreases 
from 30 mmHg prior to cTAL attachment to 12 mmHg. If the original PVR is 8 
mmHg/(L/min), PPA is reduced from 54 mmHg to 13 mmHg. 
If the cTAL were attached in series with the native lungs (PA-PA), it would likely 
result in similar PA pressure but a reduction in CO due to additive impedances and the 
increased work load of the RV. Relationships developed by Kim et al, Kuo et al, and 




[3,6,7]. The increase in pulmonary system impedance (ΔZ) due to the cTAL impedance 
(ZcTAL) can be calculated with the equation: 
ΔZ = ZcTAL f  (6) 
where f is the fraction of flow to the cTAL. If we assume CO=6 L/min and allow 4 L/min 
to travel through the cTAL then f=2/3. We will use the cTAL in vitro data at Q=4 L/min 
and HR=100 beats/min, and add either 1, 2, or 3 mmHg/(min) for the anastomoses 
resistance. Although Akay et al [6] calculated anastomoses’ resistance to be 0.87 
mmHg/(L/min), this value can vary greatly from case to case and thus we will assume a 
possible range of values for our calculations.. The Kim, Kuo, and Akay predictions for 
decrease in CO are shown in Table 3.3. 
 
Table 3.3: Kim, Kuo, Akay and average predictions for percentage decrease in CO for 
three different anastomoses’ resistances for f=2/3. 




Kim Kuo Akay Average 
1 4.1 12.8 7.6 8.2 
2 8.5 15.3 12.6 12.1 
3 12.7 17.7 17.5 16.0 
 
If the Kim and Akay data is averaged and we assume an anastomoses’ resistance of 1 
mmHg/(L/min), f=0.94 results in a 10% decrease in CO. However, if we assume a higher 




must be ≤ 0.46. Overall, these predictions are lower than previous devices and may allow 
for cTAL attachment in series in a small group of patients without significant pulmonary 
hypertension. 
Gas transfer in the cTAL is excellent with outlet PO2 and SO2 values above 240 
mmHg and 99.5%, respectively, at each tested flow rate. Thus, the cTAL exceeds its gas 
transfer goals and the fiber bundle size could be reduced in the future. This could result in 
a smaller device, offering the advantage of a smaller prime volume and a lighter, more 
“wearable” device. A shortened device would also help to eliminate any low flow or 
stasis regions near the distal end. 
In conclusion, this cTAL features excellent gas transfer and far lower impedance 
than any previous TAL. Its performance in vivo will be described in the following two 
chapters. PA-LA and PA-PA in vivo testing will examine the cTAL’s interaction with the 
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Chapter 4  
In-Parallel cTAL Attachment  
 
Introduction 
The most commonly proposed TAL attachment modes are in parallel or in series 
with the natural lungs. During in parallel attachment blood flow is routed from the 
pulmonary artery (PA), through the TAL and then returned to the left atrium (LA). In 
patients with pulmonary hypertension this attachment mode is ideal, as it reduces Z0 for 
the combined TAL and natural lung system and thus unloads the right ventricle. In this 
setting, TAL attachment should ideally result in a pulmonary system Z0 that is as close as 
possible to the healthy natural lung. To accomplish this, the combined resistance of the 
TAL and the anastomoses used to attach it must also be close to that of the healthy 
natural lung.   
The cTAL described in previous chapters was designed to meet this goal. This 
study examined pulmonary hemodynamics and cTAL function during in parallel 
attachment in healthy sheep. Device flows  of 60-90% of CO through the cTAL were 






Compliant Thoracic Artificial Lung 
 The cTAL developed and described in Chapter 3 was used for in vivo testing 
(Figure 3.1). A holder was designed out of PVC to maintain the cTAL in an upright 
position, prevent the inlet and outlet conduits from kinking, and clamp the sides of the 




 A total of five male sheep averaging 60.2 ± 1.9 kg were used in this study. All 
sheep received humane care in compliance with the “Guide for the Care and Use of 
Laboratory Animals” and all methods were approved by the University of Michigan 
Committee for the Use and Care of Animals. Anesthesia was induced with 6-9 mL/kg of 
propofol and then maintained after endotracheal intubation with 1-3% inhaled isoflurane. 
 




Sheep were mechanical ventilated with oxygen using a Narkomed 6000 ventilator (North 
American Dräger, Telford, PA). The ventilator was set to a tidal volume of 10 mL/kg and 
a frequency of 12 breaths/min and was adjusted to maintain an arterial partial pressure of 
carbon dioxide (PaCO2) between 35 and 45 mmHg.  A carotid arterial line and left 
jugular venous line were placed and then connected to fluid coupled pressure transducers 
(Hospira, Inc., Lake Forest, IL) for the continuous monitoring of arterial and central 
venous pressures (PArt and PCV). 
 A muscle sparing left thoracotomy was performed and the pulmonary artery and 
left atrium (LA) were identified. Dacron vascular grafts (Terumo, Ann Arbor, MI) for 
artificial lung attachment were attached to the PA and LA. An ultrasonic perivascular 
flow probe (Transonic 24AX, Transonic Systems, Inc., Ithaca, NY) was placed around 
the PA, proximal to the device inlet graft. This probe was connected to a flow meter 
(T400, Transonic Systems, Ithaca, NY) to allow for the measurement of PA flow (QPA). 
A pressure catheter (Becton Dickinson and Co., Franklin Lakes, NJ) was then inserted at 
the proximal PA and connected to a transducer for the display and recording of the PA 
pressure (PPA). A Rommel tourniquet was placed around the distal PA to allow for the 
adjustment of flow through the cTAL. Prior to device attachment, 1g of 
methylprednisolone (Solu-Medrol, Pfizer, New York, NY) was administered and the 
animal was anticoagulated with 100 IU/kg of intravenous sodium heparin (Baxter 
Healthcare Corp., Deefield, IL) to maintain active clotting times of above 300 seconds.  
 The cTAL was primed with heparanized saline (10 U/mL) and then connected to 





An ultrasonic flow probe (Transonic 14PXL, Transonic Systems, Inc., Ithaca, NY) was 
placed around the inflow conduit and connected to a flow meter (T400, Transonic 
Systems Inc., Ithaca, NY) in order to measure device flow (QcTAL). Pressure transducers 
were connected to the device inlet and outlet to acquire device inlet and outlet pressure 
(Pin and Pout). A suction line was attached to the cTAL gas outlet and 95:5% O2:CO2 with 
2-3% vaporized isoflurane between 3 and 9 L/min was used as the sweep gas through the 
gas inlet. Sweep gas flow was adjusted during cTAL use to maintain PaCO2 between 35 
and 45 mmHg. A Hoffmann clamp was placed around the cTAL outlet conduit to restrict 
flow through the device. After cTAL attachment, clamps on the cTAL inlet and outlet 
conduits were removed and the Hoffmann clamp was slowly loosened until QcTAL= 1 
L/min was achieved. This flow was maintained for 10 minutes for equilibration of fluid 
volumes and any inflammatory response. After device attachment, CVP decreased related 
 





to the systemic inflammatory response and 500 mL of hetastarch and 500 – 1000 mL of 
crystalloid were administered to restore CVP back to baseline values. Thereafter, the 
device conduits were clamped off and baseline data was taken, marking the start of the 
experiment. 
 A hemodynamic data set of QPA, QcTAL, Part, PCV, PPA, Pin, Pout were digitally 
acquired for 10 seconds at a sampling frequency of 250 Hz through a BIOPAC data 
acquisition system (BIOPAC, Goleta, CA). Before attaching the cTAL, an animal 
baseline data set was acquired. Rest and exercise conditions were simulated using a 
continuous dobutamine (Hospira Inc., Lake Forest, IL) infusion of 0 and then 5 
mcg/kg/min, respectively. At each dose, the hemodynamic data set was acquired at 
baseline (QcTAL = 0 L/min) and conditions of 60, 75, and 90% of CO shunted to the cTAL 
(100*QcTAL/QPA), created by tightening the Rommel tourniquet around the PA. At each 
condition, 10 minutes were allowed for equilibration before data was taken. Also, at each 
condition, a device exit gas sample was taken along with blood samples from the animal, 
device inlet and device outlet. 
 
Data Analysis 
The zeroth harmonic pulmonary input impedance modulus, Z0, was calculated at 





Z   (1) 
where P0 is the mean PA pressure and Q0 is the mean PA blood flow rate.  










   (2) 
where Pin is the cTAL inlet pressure, Pout is the cTAL outlet pressure, and QcTAL is cTAL 
flow. Data collected from device inlet and outlet blood gas samples were used to 
calculate oxygen transfer rates, VO2, as done in Chapter 3 (equation 4). Comparisons 
were performed on the data, separately for rest and exercise sets, with SPSS 19 (SPSS, 
Chicago, IL). A mixed model was used with sheep number as the subject variable and 
flow condition (percentage of flow to the cTAL) as the fixed, repeated-measure variable. 
All data is reported as mean ± standard error with a p-value of 0.05 or less being 




Before cTAL attachment, average animal baseline CO, mean arterial pressure 
(MAP), mean PA pressure (mPAP), central venous pressure (CVP), and Z0 was 6.4 ± 
0.59 L/min, 87.7 ± 8.08 mmHg, 18.2 ± 1.34 mmHg, 6.83 ± 1.22 mmHg and 2.99 ± 0.41 
mmHg/(L/min), respectively. The effect of cTAL attachment on the sheep’s CO is shown 





Without dobutamine, the baseline CO was 5.5 ± 0.65 L/min and was maintained at or 
above this level until 90% flow to the cTAL. At 90% flow to the cTAL, there was a 
negligible, 0.33% decrease in CO from baseline which was not significant (p=0.94). At 5 
mcg/kg/min of dobutamine, baseline CO was 7.23 ± 0.70 L/min and was maintained 
above this level until it decreased to 6.88 ± 0.69 L/min at 90% flow to the cTAL. This 
5.6% drop was also not significant (p=0.36).  
 Figure 4.4 displays Z0 for increasing flow to the cTAL.  
 
Figure 4.3: Cardiac output at varying percentages of cardiac output diverted to the 






For both rest and dobutamine-simulated exercise conditions, Z0 decreases from baseline 
with 60% flow to the cTAL. Without dobutamine, Z0 remains below baseline at all 
conditions. At 5 mcg/kg/min of dobutamine, baseline Z0 decreases due to increased blood 
flow to the natural lungs. As more flow is diverted to the TAL, Z0 is initially relatively 
constant but begins to rise at 75% flow. As the natural lung is increasingly excluded, Z0 
then rises towards the same Z0 as without dobutamine. At 90% flow, Z0 has increased 
50% above the 5 mcg/kg/min dobutamine baseline and is almost equivalent to all 0 
mcg/kg/min conditions. This increase was significant (p=0.049) when compared to 
baseline. 
 
Figure 4.4: Zeroth harmonic impedance modulus, Z0, at varying percentages of cardiac 





 MAP and mPAP for both dobutamine levels are displayed in Table 4.1 at each 
target and actual percent flow to the cTAL.  
 
Table 4.1: Mean pulmonary artery pressure and mean arterial pressure for varied 
percentages of the cardiac output to the cTAL 








0 mcg/kg/min     
 BL – 0% 0 ± 0% 25.1 ± 5.3 78.4 ± 12.6 
 60% 62 ± 1% 21.6 ± 4.2 72.3 ± 6.6 
 75% 74 ± 2% 22.0 ± 4.6 73.5 ± 7.8 
 90% 91 ± 2% 24.3 ± 5.2 73.1 ± 7.8 
5 mcg/kg/min     
 BL – 0% 0 ± 0% 20.5 ± 1.5 78.5 ± 5.0 
 60% 61 ± 2% 20.5 ± 2.6 73.2 ± 2.6 
 75% 76 ± 2% 26.5 ± 3.2 73.7 ± 6.1 
 90% 93 ± 2% 29.4 ± 3.6 67.3 ± 6.9 
BL = baseline; CO = cardiac output; cTAL = compliant thoracic artificial lung; MAP = 
mean arterial pressure; mPAP = mean pulmonary artery pressure 
 
The mean baseline PA pressure at 0 mcg/kg/min dobutamine was 25.1 ± 5.31 mmHg 
with no significant change at 60, 75 and 90% flow to the cTAL (p = 0.35, 0.46, and 0.86). 




29.4 ± 3.61 mmHg at 90% flow to the cTAL; however, this increase approached but was 
not significant (p=0.09). Baseline MAP was 78.4 ± 12.6 mmHg with no dobutamine and 
decreased slightly to 73.1 ± 7.82 mmHg at 90% flow to the cTAL. With 5 mcg/kg/min of 
dobutamine, baseline MAP was 78.5 ± 4.98 mmHg and decreased to 67.3 ± 6.92 mmHg 
at 90% flow to the cTAL; however, this decrease was not significant (p=0.16). 
 
Device Performance 
 Device resistance at various flow rate ranges is shown in Figure 4.5.  
 
Resistance of the cTAL remains relatively constant at all tested flow rates.  Device 
resistance averaged 0.51 ± 0.01 mmHg/(L/min), ranging from 0.50 ± 0.01 mmHg/(L/min) 
at 2-3 L/min to a maximum of 0.55 ± 0.02 mmHg/(L/min) at 5-6 L/min. Accordingly, 
 





device flow did not significantly effect resistance (p=0.29). Though this was not 
primarily a gas exchange experiment, the cTAL also exchanged gas effectively. Arterial 
PO2, PCO2 and pH, along with cTAL O2 and CO2 gas transfer rates (VO2 and VCO2) are 
displayed in table 4.2 for each device flow condition.  
 
Table 4.2: Arterial PO2, PCO2 and pH, and cTAL O2  transfer rates (VO2) for varied 

















    
 
 60% 439 ± 57 38.9 ± 1.3 7.40 ± 0.01 85.7 ± 7.7 
 75% 460 ± 49 38.7 ± 1.3 7.41 ± 0.01 96.0 ± 6.8 
 90% 442 ± 35 37.1 ± 3.6 7.40 ± 0.01 109.1 ± 8.2 
5 
mcg/kg/min 
    
 
 60% 399 ± 37 43.6 ± 1.6 7.37 ± 0.02 
103.3 ± 
11.1 
 75% 442 ± 35 45 ± 1.8 7.36 ± 0.02 
120.7 ± 
10.9 
 90% 422 ± 38 44.4 ± 1.3 7.36 ± 0.01 155.5 ± 8.8 






The device outlet oxyhemoglobin saturations were above 99% at every flow condition, 
although venous conditions were not sufficient to challenge the device. A typical 
hemoglobin and device inlet PO2 was 7.5 and 80 mmHg, respectively. Even with this 
higher inlet PO2, VO2 rates ranged from 85.7 ± 7.7 mL/min at 0 dobutamine and 60% CO 
to the cTAL to 155.5 ± 8.8 mL/min at 5 dobutamine and 90% CO to the cTAL. Lastly, at 
the conclusion of the experiment, there was no visible clot formation in the device. 
  
Discussion 
 To date, there is no commercially available TAL. Over 18 years of development, 
these devices have always featured excellent gas exchange and research has thus focused 
on developing devices with progressively lower blood flow resistance and improved 
hemodynamics during in vivo attachment [Cook, Cook, Sato]. Ideally, TALs should be 
able to provide the majority of the gas exchange while being able to maintain normal 
pulmonary hemodynamics.  
 As there is no commercial device for this application, a few groups have 
investigated clinical PA-LA attachment in cases of severe pulmonary hypertension using 
the lowest resistance gas exchanger on the market, the Novalung ILA.  Two of these 
patients had primary pulmonary hypertension and four had pulmonary veno-occlusive 
disease. Five of the patients (87%) were successfully bridged [Schmid, Camboni, 
Strueber]. Despite this success, the Novalung was not designed for this application.  Its 
intended use is arterio-venous CO2 removal, which features much lower blood flows of 2 




are low for the application and the resistance is approximately 5-6 mmHg/(L/min) at 
blood flows of 2-2.5 L/min [Florchinger, Muller, Wiebe]. To support COPD, IPF, and 
septic patients, greater gas exchange will be required. Moreover, in cases of marked 
pulmonary hypertension, it would be ideal to be able to fully unload the RV and eliminate 
the need for inotropes. 
 In the current study, the new cTAL design was tested in healthy animals with 
normal PA pressure. Therefore, the goal for this study was to maintain normal PA 
pressures and CO with up to 90% of CO diverted to the cTAL. Results indicate that these 
goals were met. cTAL attachment caused only minimal, statistically insignificant 
decreases in CO and increases in PA pressure from baseline at all conditions. At the most 
extreme condition, simulated exercise with 90% of the CO diverted to the cTAL, CO 
decreased 5.6% and PA pressure increased 8.8 mmHg.  This, however, represents an 
extreme case.  A more typical, and advisable [Takewa], condition would likely be 75% of 
CO.  Here, CO was identical to baseline values, and PA pressure decreased at rest and 
increased a small amount during simulated exercise. 
 Maintenance of normal pulmonary hemodynamics was the result of very low 
cTAL resistance. Average resistance for the range of flows tested was 0.51 ± 0.01 
mmHg/(L/min), well below that of the natural lung. Moreover, the resistance of the 
device did not change significantly as flow increased. The low cTAL resistance, in turn, 
maintains low Z0. Previous studies have shown that Z0 is the dominant variable affecting 
CO during TAL attachment, with CO decreasing as Z0 increases [Kim, Kuo, Akay]. In 
this study, Z0 is lower than baseline at 60% flow to the cTAL due to the second, parallel 




the PA is banded further, the natural lung portion of the system is closed, the percentage 
of flow to the cTAL increases, and Z0 increases slightly. However, since device resistance 
remains low, the resulting Z0 remains small and similar to that of healthy natural lungs. 
At 5 mcg/kg/min of dobutamine, however, high CO and PA pressure leads to lower 
baseline Z0.  As flow is diverted to the cTAL, Z0 then increases to the same level seen 
with in the 0 dobutamine case. 
 Based on these results, the cTAL will be able to completely unload the right 
ventricle in vivo during PA-LA attachment in patients with any degree of pulmonary 
hypertension. To examine this, one can use the equation PPA=CO*R+PLA, where PPA is 
the PA pressure, PLA is the left atrial pressure, and CO is cardiac output. R is the 
resistance of the parallel artificial and natural lung system. If there is no PA banding, R =  
[RN*(RT+RA)]/[RN+RT+RA)], in which RN is the natural lung resistance, RT is the TAL 
resistance, and RA is the resistance of the TAL anastomoses or cannulae. For CO = 6 
L/min, PLA = 6 mmHg, RT = 0.5 mmHg/(L/min),  and RA = 0.87 mmHg/(L/min), and RN = 
9 mmHg/(L/min) [10], the PA pressure prior to attaching the TAL would be 60 mmHg. 
With the cTAL, it falls to 13 mmHg. In comparison, under the same conditions, the 
Novalung ILA (RT = 6 mmHg/(L/min)) would reduce PA pressure to 29 mmHg. 
 The other experimental TAL in development is the Biolung® (MC3, Ann Arbor, 
MI). The hard-shell Biolung was tested in a study similar to this one [Akay 2]. The only 
exception is that Akay et al simulated rest (no dobutamine), ambulatory (2 mcg/kg/min 
dobutamine), and exercise (5 mcg/kg/min dobutamine) conditions. Results showed that 
CO was maintained as the percentage of CO to the device increased at resting and 




TAL up to 23 ± 5% at 90% flow diverted through the TAL. Direct comparison between 
these two studies is difficult, as the baseline Z0 and baseline cardiac response to 
dobutamine varied greatly. In the Biolung study, baseline Z0 were lower and, as a result, 
baseline CO was greater at the same dobutamine doses. Thus, the easiest means of 
comparison between these studies is the Z0 with 90% of cardiac output through the 
artificial lung. Here, hemodynamics are largely unaffected by natural lung resistance. At 
90%, Z0 ranged from 4.5-4.9 in the Biolung study and 4.1-4.5 in the cTAL study. This 
small difference is similar to what one would predicted by the difference in TAL 
resistances in these studies.  The cTAL resistance is approximately 0.3 mmHg/(L/min) 
smaller with flow rates of 2-3 L/min and approximately 0.65 mmHg/(L/min) lower at 
flow rates of 5-6 L/min. Thus the Biolung should provide slightly less but similar 
unloading. 
Ultimately, this study suggests that the cTAL is capable of being used clinically, 
in parallel with the native lungs and under high flow conditions. Minimal decreases in 
CO were seen at 90% flow to the device at both dobutamine levels, indicating exercise 
would be possible during cTAL attachment. Since cTAL resistance is small, flow should 
route preferentially through the device. This attachment mode would be ideal for patients 
with high pulmonary vascular resistance since the device resistance would be much lower 
than the native lung resistance. Approximately 57% of CO went through the cTAL with 
no PA banding during this experiment. Assuming a pulmonary vascular resistance of 2.25 
mmHg/(L/min) in patients with pulmonary hypertension, about 70% of the CO would 
flow preferentially through the cTAL with no PA banding. Further testing of in parallel 




effects of in parallel cTAL attachment will also be studied for up to 30 days in healthy 
sheep and sheep with pulmonary hypertension. 
 
Conclusion 
The cTAL resistance is lower than the natural lung, averaging 0.51 ± 0.03 
mmHg/(L/min). Use of the cTAL in a PA-LA configuration caused no change in CO 
under rest and exercise conditions. Thus, the cTAL can provide PA-LA respiratory 
support without significant changes in pulmonary hemodynamics in healthy sheep and 





1. Cook KE: Design and Testing of Intrathoracic Artificial Lungs. PhD Thesis. 
Northwestern University, 1996. 
2. Cook KE, Perlman CE, Seipelt R, et al: Hemodynamic and Gas Transfer 
Properties of a Compliant Thoracic Artificial Lung. ASAIO J 51: 404-411, 2005. 
3. Sato H, McGillicuddy JH, Griffith GW, et al: Effect of Artificial Lung 
Compliance on In Vivo Pulmonary System Hemodynamics. ASAIO J 52: 248-256, 
2006. 
4. Schmid C, Philipp A, Hilker M, et al. Bridge to Lung Transplantation Through a 
Pulmonary Artery to Left Atrial Oxygenator Circuit. Ann Thorac Surg 85:1202-5, 
2008. 
5. Camboni D, Philipp A, Arlt M, et al. First Experience With a Paracorporeal 
Artificial Lung in Humans. ASAIO J 55:304-307, 2009. 
6. Strueber M, Hoeper MM, Fischer S, et al. Bridge to Thoracic Organ 
Transplantation in Patients with Pulmonary Arterial Hypertension Using a 
Pumpless Lung Assist Device. American Journal of Transplantation 9:853-857, 
2009. 
7. Flörchinger B, Philipp A, Klose A, Hilker M, Kobuch R, Rupprecht L, Keyser A, 
Pühler T, Hirt S, Wiebe K, Müller T, Langgartner J, Lehle K, Schmid C. 
Pumpless extracorporeal lung assist: a 10-year institutional experience. Ann 
Thorac Surg 86:410-7, 2008. 
8. Müller T, Lubnow M, Philipp A, Bein T, Jeron A, Luchner A, Rupprecht L, Reng 




GA, Pfeifer M. Extracorporeal pumpless interventional lung assist in clinical 
practice: determinants of efficacy. Eur Respir J 33:551-8, 2009. 
9. Wiebe K, Poeling J, Arlt M, Philipp A, Camboni D, Hofmann S, Schmid C. 
Thoracic surgical procedures supported by a pumpless interventional lung assist. 
Ann Thorac Surg 89:1782-7, 2010. 
10. Takewa Y, Tatsumi E, Taenaka Y, Eya K, et al. Hemodynamic and humoral 
conditions in stepwise reduction of pulmonary blood flow during venoarterial 
bypass in awake goats. ASAIO J 43(5): M494-9, 1997. 
11. Kim J, Sato H, Griffith GW, Cook KE. Cardiac output during high afterload 
artificial lung attachment. ASAIO J 55: 73-77, 2009. 
12. Kuo AS, Sato H, Reoma JL, Cook KE. The relationship between pulmonary 
system impedance and right ventricular function in normal sheep. Cardiovascular 
Engineering 9: 153-160, 2009. 
13. Akay B, Foucher JA, Camboni D, Koch KL, Kawatra A, Cook KE. 
Hemodynamic design requirements for in series thoracic artificial lung attachment 
in a model of pulmonary hypertension.  ASAIO Journal, submitted. 
14. Akay B, Reoma JL, Camboni D, et al. In-parallel artificial lung attachment at 





Chapter 5  
In-Series cTAL Attachment 
 
Introduction 
While the cTAL had excellent in vivo performance in parallel, there is the 
constant risk of life-threatening air emboli and thromboemboli in this attachment mode. 
An alternative configuration is in series attachment with the natural lungs. In this mode, 
blood is routed from the proximal pulmonary artery (PA) through the cTAL and then 
back to the distal PA where the blood then flows through the native lungs and finally 
back to the LA. This configuration eliminates the risk of systemic emboli by allowing the 
lung to perform its filtration and non-respiratory functions. In addition, the entire cardiac 
output (CO) can flow through the cTAL, allowing for complete gas exchange. However, 
studies on TAL attachment mode have shown series attachment to increase pulmonary 
system impedance and decrease CO [1]. Increased pulmonary system impedance is 
caused by the additive impedance of the TAL and natural lung. Therefore, it is imperative 
that the device have the lowest impedance possible to prevent RV failure when attached 
in series. 
The low-resistance cTAL developed and tested in previous chapters was 
examined in this setting. This study examined pulmonary hemodynamics and cTAL 




in Chapter 4, different device flows were tested with 60-90% of CO through the cTAL 




 Five male sheep averaging 63 ± 0.92 kg were used in this study. All sheep 
received humane care in compliance with the “Guide for the Care and Use of Laboratory 
Animals” and all methods were approved by the University of Michigan Committee for 
the Use and Care of Animals. Anesthesia was induced with 6-9 mL/kg of propofol and 
then maintained after endotracheal intubation with 1-3% inhaled isoflurane (Abbot 
Laboratories, Chicago, IL). Sheep were mechanically ventilated with oxygen using a 
Narkomed 6000 ventilator (North American Dräger, Telford, PA). The ventilator was set 
to a tidal volume of 10 mL/kg and a frequency of 12 breaths/min and was adjusted to 
maintain an arterial PCO2 (PaCO2) between 35 and 45 mmHg.  A carotid arterial line and 
left jugular venous line were placed and then connected to fluid coupled pressure 
transducers (ICU Medical, Inc., San Clemente, CA) for the continuous monitoring of 
arterial and central venous pressures (PArt and PCV). 
A muscle sparing left anterolateral thoracotomy was performed and the fourth rib 
was removed. The left lung was packed laterally and the pericardium was incised. The 
PA was then identified. Low porosity woven Dacron vascular grafts 18 mm in size 
(Boston Scientific, Natick, MA) solvent bonded to 5/8” inner diameter PVC tubing 
(Fisher Scientific, Pittsburgh, PA) were used as conduits for artificial lung attachment. 




distal PA near the bifurcation. The device inlet end-to-side anastomosis was then 
performed on the proximal PA. An ultrasonic perivascular flow probe (Transonic 24AX, 
Transonic Systems, Inc., Ithaca, NY) was placed around the PA, proximal to the device 
inlet graft. This probe was connected to a flow meter (T400, Transonic Systems, Ithaca, 
NY) to allow for the measurement of PA flow (QPA). A pressure catheter (Becton 
Dickinson and Co., Franklin Lakes, NJ) was then inserted at the proximal PA and 
connected to a transducer for the display and recording of the proximal PA pressure 
(PPAP). A Rommel tourniquet was placed around the PA between the inlet and outlet 
grafts to allow for the adjustment of flow through the cTAL. Pressure catheters were 
inserted into the distal PA near the bifurcation and into the left atrium to allow for the 
recording of the distal PA pressure (PPAD) and the left atrial pressure (PLA), which 
facilitated the calculation of the pulmonary vascular resistance (PVR) of the native lungs. 
Prior to device attachment, 1g of methylprednisolone (Solu-Medrol, Pfizer, New York, 
NY) was administered, and the animal was anticoagulated with 100 IU/kg of intravenous 
sodium heparin (Baxter Healthcare Corp., Deerfield, IL) to maintain active clotting times 
of above 300 seconds. 
 The cTAL was primed with heparinized saline (10 U/mL) and then connected to 





An ultrasonic flow probe (Transonic 14PXL, Transonic Systems, Inc., Ithaca, NY) was 
placed around the inflow conduit and connected to a flow meter (T400, Transonic 
Systems Inc., Ithaca, NY) in order to measure device flow (QcTAL). Device inlet and outlet 
pressure (Pin and Pout) were measured by fluid-coupled pressure transducers. A suction 
line was attached to the cTAL gas outlet and 95:5% O2:CO2 with vaporized isoflurane (1-
3%) was used as the sweep gas through the gas inlet. Sweep gas flow was adjusted during 
cTAL use to maintain PaCO2 between 35 and 45 mmHg. A Hoffmann clamp was placed 
around the cTAL outlet conduit to restrict flow through the device. After cTAL 
attachment, clamps on the cTAL inlet and outlet conduits were removed and the 
Hoffmann clamp was loosened until 1 L/min flow to the cTAL was achieved. This flow 
was maintained for 10 minutes for equilibration of fluid volumes and any inflammatory 
response. After device attachment, CVP decreased related to the systemic inflammatory 
response and up to 500 mL of hetastarch and 500 mL of crystalloid were administered to 
 





restore CVP back to baseline values, if required. Thereafter, the device conduits were 
clamped off and baseline data was taken. 
 A hemodynamic data set of QPA, QcTAL, Part, PCV, PPA, Pin, Pout were digitally 
acquired for 10 seconds at a sampling frequency of 250 Hz through a BIOPAC data 
acquisition system (BIOPAC, Goleta, CA). Rest and exercise conditions were simulated 
using a continuous dobutamine (Hospira Inc., Lake Forest, IL) infusion of 0 and then 5 
mcg/kg/min, respectively. At each dose, the hemodynamic data set was acquired at 
baseline, with no flow to the device, and conditions of 60, 75, and 90% of CO shunted to 
the cTAL (QcTAL/QPA), created by tightening the Rommel tourniquet around the PA. At 
each condition, 10 minutes were allowed for equilibration before data was taken. Also, at 
each condition, a device exit gas sample was taken along with blood samples from the 




The zeroth harmonic pulmonary input impedance modulus, Z0, was calculated at 
each flow condition (equation 1, Chapter 4). Z0 has been shown previously by our group 
to be an excellent index for predicting right ventricular function in high afterload states 
[2,3]. Device resistance, RcTAL, was also calculated at each flow condition (equation 2, 









where PPAD is the mean distal PA pressure, PLA is the mean left atrial pressure, and Q0 is 
the mean PA blood flow rate (CO).  
 The resistance of the graft anastomoses, Ra, was calculated by analyzing all the 
resistive elements in the experimental pulmonary system setup (Figure 5.2). 
  





  (2) 
where PPAP is the mean proximal PA pressure. Shunt resistance, Rs, was calculated by 
assuming it was an element in series with the native lungs: 
PVRRR Ts   (3) 
By assuming the anastomoses were a resistive element in series with the cTAL, which 
was in parallel with the flow occluder, the following relationship was determined: 
 
Figure 5.2: Experimental pulmonary system setup with all resistive elements. The 
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where f is the fraction of Q0 diverted to the cTAL. Using equations 4 and 5, an equation 





R   (6) 
Ra was calculated at each flow condition and an equation for approximate Ra as a 
function of f was determined. 
Statistical analysis was performed separately for the 0 and 5 mcg/kg/min data 
sets. The analysis of baseline PVR before and after cTAL attachment was conducted 
using a paired two-tailed student’s t-test assuming equal variances. All other statistical 
comparisons were performed using a mixed model with sheep number as the subject 
variable and flow condition as the fixed, repeated-measure variable. The statistical 
analysis was performed using SPSS 19 (SPSS, Chicago, IL). All data is reported as the 





Before cTAL attachment, average animal baseline CO, mean arterial pressure 




± 0.56 L/min, 87.6 ± 6.20 mmHg, 25.6 ± 0.90 mmHg, 12.1 ± 1.17 mmHg, 1.62 ± 0.32 
mmHg/(L/min), and 4.05 ± 0.39 mmHg/(L/min), respectively. The effect of cTAL 
attachment on the sheep’s CO is shown in Figure 5.3.  
 
Without dobutamine, the baseline CO of the sheep following cTAL attachment was 6.20 
± 0.53 L/min. This decreased 13% to 5.40 ± 0.34 L/min at 60% flow to the cTAL 
(p=0.922), 25% to 4.66 ± 0.31 L/min at 75% flow to the cTAL (p=0.07), and 35% to 4.05 
± 0.27 L/min at 90% flow to the cTAL (p=0.01). The CO did not drop significantly until 
greater than 75% of CO was diverted to the cTAL. After starting dobutamine at 5 
mcg/kg/min, CO increased to 7.85 ± 0.70 L/min at baseline with no flow to the cTAL. 
Once again, CO decreased with increasing flows to the cTAL, dropping 4.9% to 7.46 ± 
 
Figure 5.3: Cardiac output at varying percentages of cardiac output diverted to the 




0.55 L/min, 12% to 6.93 ± 0.51 L/min, and 24% to 5.96 ± 0.44 L/min with 60, 75%, and 
90% of CO going through the cTAL, respectively. These decreases in CO were not 
significant at any of the conditions (p=0.13). 
Similarly, MAP decreased with increasing flow to the TAL (Figure 5.4).  
 
At 0 mcg/kg/min dobutamine, baseline MAP was 81 ± 4.0 mmHg and increased slightly 
to 83 ± 5.7 mmHg at 60% flow to the cTAL before decreasing to 76 ± 6.1  mmHg and 67 
± 5.0 mmHg at 75% and 90% flow to the cTAL, respectively (p=0.18). With 5 
mcg/kg/min of dobutamine, baseline MAP was 84 ± 5.3 mmHg.  This decreased to 80 ± 
6.9 mmHg at 60% flow to the cTAL (p=0.99), 69 ± 2.8 mmHg at 75% flow to the cTAL 
 
Figure 5.4: Mean arterial pressure, MAP, at varying percentages of cardiac output 




(p=0.22), and then fell significantly to 60 ± 1.3 mmHg at 90% flow to the cTAL 
(p=0.01). 
Z0 increased with increasing flow to the cTAL (Figure 5.5). 
 
Without dobutamine, baseline Z0 was 4.66 ± 0.56 mmHg/(L/min) and increased to 7.02 ± 
0.56 mmHg/(L/min) at 75% flow to the cTAL (p=0.06) and 8.35 ± 0.67 mmHg/(L/min) 
at 90% flow to the cTAL (p<0.01). Baseline Z0 in the simulated exercise condition was 
4.27 ± 0.77 mmHg/(L/min) which slightly increased to 5.11 ± 0.19 mmHg/(L/min) at 
75% flow to the cTAL (p=0.99). Z0 increased significantly to 6.48  ± 0.45 mmHg/(L/min) 
once 90% flow to the cTAL was achieved (p<0.05).  
 
Figure 5.5: Zeroth harmonic impedance modulus, Z0, at varying percentages of cardiac 




 Although Z0 increased with increasing levels of PA occlusion, the mPAP 
(proximal) remained fairly stable under all of the rest and exercise conditions due to 
decreasing CO (Figure 5.6).  
 
Baseline mPAP without dobutamine was 28 ± 2.0 mmHg and increased by an 
insignificant amount to 33 ± 2.5 mmHg at 90% flow to the cTAL (p=0.53). Similarly, the 
baseline mPAP of 32 ± 4.8 mmHg increased insignificantly to 38  ± 0.6 mmHg at 90% 
flow to the cTAL under simulated exercise conditions (p=0.57). 
 The decrease in CO seen in Figure 5.3 is due to an increase in total pulmonary 
system resistance, RT. An increase in RT at each condition is either due to an increase in 
PVR or everything prior to the native lungs (shunt resistance), Rs. The contribution of 
PVR and Rs to RT is displayed in Figure 5.7. 
 
Figure 5.6: Mean proximal pulmonary artery pressure, mPAP, at varying percentages 







Figure 5.7: Total pulmonary system resistance, RT, pulmonary vascular resistance, 
PVR, and shunt resistance, Rs, at varying percentages of cardiac output diverted to 




Baseline PVR, before cTAL attachment, was 1.61 ± 0.32 mmHg/(L/min). After attaching 
the cTAL, allowing flow to the device for 10 minutes, and then clamping off the device 
for baseline data, PVR increased substantially to 3.13 ± 0.17 mmHg/(L/min) (p=0.01). 
However, no further significant increase was seen with increasing percentage of CO to 
the cTAL (p=0.10). After the initiation of dobutamine, PVR decreased to 2.23 ± 0.45 
mmHg/(L/min) at baseline. This represented a substantial drop from the baseline of the 
rest condition, although this did not achieve statistical significance (p=0.16). Again, PVR 
was unchanged as the percentage of COto the cTAL was increased. However, as the 
percentage of CO to the cTAL increases, Rs increases significantly at both rest and 
exercise conditions (p<10-3). From Figure 5.7 it is apparent that the elevation in RT with 
increasing flow to the cTAL is due to Rs. Increases in Rs must be due to either an increase 





As percentage of CO to the cTAL increases, Ra increases. A linear relationship between f 
and Ra was determined: 
Ra = 1.77f + 1.31, R
2 = 61.7% 
RcTAL does not increase with increasing percentage of CO to the cTAL. Thus, increases in 
shunt resistance are due to increases in Ra and not RcTAL. Overall, Ra is 4-6 times larger 




Figure 5.8: cTAL resistance, RcTAL, and anastomoses’ resistance, Ra, at varying 





Device Function  
The resistance of the cTAL was also assessed as a function of overall flow rate 
through the device (Figure 5.9). RcTAL did not change significantly with flow rate 
(p=0.16), averaging 0.46 ± 0.02 mmHg/(L/min) over the entire range of flows.  
 
The cTAL also performed well in terms of gas transfer and biocompatibility. Due 
to relatively high venous saturations (approximately 85%) and lower hemoglobin (6.11 ± 
0.17 g/dL), the gas transfer function of the device was never challenged. Arterial blood 
gas hemoglobin oxygen saturations were maintained at near 100% for all of the 
conditions. Finally, all of the devices functioned without failure for the entire duration (3-
4 hours) of the experiment and there was no visible clot formation within the device at 
the conclusion of the experiment.  
 






As discovered in Chapter 4, cTAL resistance did not change significantly with 
flow. In the current study, average cTAL resistance was 0.46 ± 0.02 mmHg/(L/min), 
similar to results from Chapter 4. Though cTAL resistance did not increase with 
increasing percentage flow to the device, Z0 did increase. This increase was due to an 
increase in the shunt resistance and not PVR. There was an initial 94% increase in PVR 
from animal baseline during an initial equilibration phase following attachment of the 
cTAL due to an inflammatory response to the device. However, after this initial increase, 
the PVR did not increase significantly as percentage flow to the cTAL increased. 
Resistance of the shunt did, however, increase with increasing flow. Thus, increases in 
pulmonary system resistance with increasing flow diversion to the cTAL were due to 
increasing resistance of the anastomoses. These values were higher than predicted 
previously [4] but anastomoses’ resistance can vary greatly from case to case. 
Theoretically, at baseline (no flow to the cTAL), RT should have equaled PVR; however, 
this was not the case. There was a small additional resistance in the system, most likely 
from the anastomoses, suggesting the anastomoses cannot be treated as an element 
completely in series with the cTAL. 
Based on previous predictions and the results in this chapter, we can make 
predictions on how much flow through the cTAL could be tolerated by patients. As 
discussed in earlier chapters, previous studies concluded that Z0 is the dominant variable 
affecting CO during TAL attachment, with CO decreasing as Z0 increases [2-4]. This was 




to the cTAL increased, Z0 increased, causing CO to decrease. CO only decreased 
significantly at 90% of CO to the cTAL with 0 mcg/kg/min dobutamine. However, at the 
other conditions, there were percent decreases in CO that would not be acceptable for 
patient use. At 60% flow to the cTAL, with 0 and 5 mcg/kg/min, CO decreased 13% and 
5%, respectively. Therefore, cTAL flows above 60% of CO are not advisable during PA-
PA attachment in patients. From their study on the effects of impedance during PA-PA 
attachment, Akay et al determined that TAL resistance must be less than 1.81, 0.92, and 
0.47 mmHg/(L/min) for 50, 75, and 100% of CO to the TAL to limit the drop in CO to 
less than 10%. However, they also calculated resistance of the anastomoses to be 0.87 
mmHg/(L/min). In our study, the anastomoses resistance went up with increasing flow to 
the device and averaged 2.64 mmHg/(L/min). In Chapter 3, it was predicted that with an 
anastomoses’ resistance of 3 mmHg/(L/min), the percentage flow to the cTAL must be 
less than 46% for a decrease in CO less than 10%. Using the average cTAL and 
anastomoses’ resistance presented in this chapter, the percentage of CO to the cTAL must 
be ≤ 53% to maintain CO within 10% of baseline. Therefore, if anastomoses’ resistance 
is high, as in this study, the percentage of CO to the cTAL during PA-PA attachment 
should be kept around 50%. This warrants further examination in long-term cTAL 
studies. Results in these studies may vary due to additional variables, including 
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Chapter 6  
Conclusion 
Conclusions 
This work examined the effect of different housing geometries and materials on 
TAL impedance and flow uniformity. From CFD and in vitro studies, the optimal TAL 
geometry was determined.  A cTAL with this design was prototyped for in vitro and in 
vivo testing. The in vivo performance of the optimized cTAL was tested in two different 
attachment modes under simulated rest and exercise conditions. From these studies, it can 
be concluded that: 
1. More gradual device entrances and exits result in reductions in TAL impedance. 
Recirculation in the inlet housing region is reduced as θ decreases, reducing 
overal device impedance. This was also the case for the cTAL, as confirmed by 
FSI analysis. 
2. A region of little to no flow exists near the distal end of the TAL and cTAL in the 
15° and 45° models. These areas were largest in the 15° model where flow was 
barely reaching past the middle of the housing body. This low flow region could 
lead to reduced gas transfer performance and clot formation over time. 
3. Flow is uniform through the fiber bundle, with a resistance of about 0.30 





4. Average housing displacement was greatest in the 15° model. Thus, more flow 
dampening occurred for smaller θ. The velocity entering the bundle at peak 
systole was highest in the 90° model, indicating that flow was less temporally 
uniform in this model due to lower dampening of the flow pulse. Low flow during 
diastole could also lead to stasis and clot formation. 
5. The 45° model had the optimal combination of low impedance, better flow 
patterns, and relatively compact size. Thus, it was chosen for the cTAL prototype 
and tested in vivo. 
6. The effect of flow rate on impedance was different in the hard-shell TAL and the 
cTAL. TAL Z0 increased linearly with SV, while cTAL Z0 decreased slightly with 
increasing SV. The cTAL had lower impedance than the TAL, especially at higher 
SV. Thus, at higher flow rates, such as those experienced during exercise, there is 
a larger advantage to using the cTAL. 
7. Inlet flow pulsatility does not greatly influence TAL or cTAL impedance.  
8. The cTAL has a large compliance (5.21 ± 0.57 mL/mmHg under high pressure) 
which allows the housing to expand and dampen the flow pulse. Due to this 
expansion, the velocity of the fluid in the cTAL decreases, resulting in less 
recirculation and, as a result, lower Z0. Comparison of cTAL vector plots with 
those in the hard shell housing TAL confirmed that recirculation regions are 
smaller and have lower velocity in the cTAL. 
9. The cTAL has excellent gas transfer with outlet PO2 and SO2 values above 240 
mmHg and 99.5%, respectively, at flow rates of 3-7 L/min. Thus, the rated flow 




10. In vivo, cTAL resistance does not vary significantly with blood flow rate. During 
PA-LA and PA-PA attachment, cTAL resistance averaged 0.51 ± 0.03 
mmHg/(L/min) and 0.46 ± 0.03 mmHg/(L/min), respectively.  
11. PA-LA cTAL attachment allows for excellent exercise tolerance and will be 
capable of unloading the RV in patients with pulmonary hypertension. Under all 
flow conditions during acute in vivo testing, CO was not significantly different 
from baseline. The cTAL should be able to provide PA-LA respiratory support for 
flows up to 90% of CO. 
12. PA-PA attachment should be feasible at cTAL blood flows up to 53% of CO.  
 
Limitations and Future Work 
One limitation in this work is the ability of the CFD software to accurately model 
the experimental flow conditions. As discussed in Chapters 2 and 3, turbulent flow could 
not be applied in the fiber bundle and thus parts of the models had to be run separately. 
This worked well in the hard-shell TAL study, with CFD results matching experimental 
results fairly closely (Chapter 2). However, FSI analysis proved to be more complicated 
and a different approach was necessary to achieve physically accurate results. Because 
the outlet housing section had to be run as laminar, impedance values were higher overall 
in the FSI models, creating slight differences from the cTAL experimental results 
(Chapter 3). Despite these challenges, the CFD studies provided important information 
on the flow uniformity within the device throughout the cardiac cycle. Velocity plots 
revealed areas of little to no flow at the distal end of the device. Since the cTAL exceeded 




device would help to eliminate any low flow or stasis regions near the distal end. A 
smaller device would also offer the advantages of a smaller prime volume and a lighter, 
more “wearable” device.  
For the current cTAL design, the next step is 14 day in vivo studies in both 
healthy and pulmonary hypertension sheep models. Two long-term experiments have 
already been carried out in healthy sheep. In these studies, the cTAL was attached in the 
PA-LA configuration with no PA banding. After the animal recovered from surgery, the 
cTAL was placed in a modified backpack, attached to the sheep’s flank, and attached to 
the inlet and outlet grafts (Figure 6.1).  
 
In the first sheep, the cTAL was attached for 16 days. The second sheep was euthanized 
after three days due to inlet graft occlusion from sheep positioning and movement. Gas 
 





transfer of the device was excellent and cTAL resistance did not change significantly 
over the course of either experiment. In the first study, resistance started at 0.95 
mmHg/(L/min) and averaged 0.66±0.04 mmHg/(L/min) over the entire 16 days. At the 
conclusion of this experiment, the device was examined for blood clots. No clots were 
present, except for the sides of the bundles where it was clamped in the device holder 
(Figure 6.2).  
 
Clamping tightly on the sides of the bundle, to prevent shunting and keep the device 
firmly in place, created a static region where blood pooled. Also, the cTAL is positioned 
in the backpack such that it lies on its side, with one side of the bundle higher than the 
other. More clotting was present on the highest side due to less blood reaching that area. 
In the second sheep, modifications were made to the side clamps so they contacted less of 
the bundle. The sides were also clamped more lightly. Though attachment only lasted 
three days, this appeared to decrease clotting in the side regions.  
 
Figure 6.2: Clotting on the side of the fiber bundle where the cTAL was clamped in 





 In the future, the cTAL holder will be redesigned so the device is held in place via 
attachments to the gas caps. The minimum amount of clamping necessary to prevent 
shunting will be then be applied to the bundle sides. The possibility of creating internal 
means of preventing shunting, which would eliminate the need for any side clamping, is 
being investigated. Ultimately, long-term in vivo testing will reveal additional 
information on device longevity and tolerance in different attachment configurations, as 
well as different disease models. 
(a)  
(b)  
Figure 6.3: cTAL from 3 days of attachment in a chronic sheep, using more moderate 
clamping of the sides. No clotting in the cTAL body (a) and reduced clotting in the 





Compliant Thoracic Artificial Lung Fabrication  
 
Summary 
 The cTAL models used for testing in Chapters 3-5 in this dissertation were 
constructed with a multi-step fabrication process. The compliant cTAL housing is created 
by dipping a 4-part Delrin model (Figures A.1 and A.2) in a container of Biospan. After 
this 6 day process, the housing is removed from the dipping model and goes through an 
extensive process of testing for holes/leaks and then patching the housing. cTAL fiber 
bundles are created by winding a mat of polypropylene hollow fibers around a 
polycarbonate core. The completed fiber bundle is then inserted into the center of the 
patched housing. After trimming excess housing, the cTAL is placed in our centrifuge 
setup for potting: binding the fiber bundle and housing together. A two part polyurethane 
polymer, WC7-53 (BJB Enterprises Inc., Tustin, CA), is injected through the top of the 
spinning centrifuge which evenly distributes the material into the ends of the 
housing/fiber bundle and binds them together. After potting, the ends of the cTAL are cut 
to expose the open ends of the hollow fibers. The cTAL then undergoes another series of 
leak testing and patching to eliminate any holes and/or leaks. Acrylic gas caps are then 




for air leaks. After these are patched, the cTAL is ready for testing. Detailed protocols are 
included below for each part of the cTAL fabrication process. 
 
Dipping: Creating the cTAL Housing 
Percent Solid 
 Before beginning the dipping process, the Biospan must be checked for the 
correct percent solid formulation as described below. 
1. Weigh a weigh dish three times, zeroing after each time. 
2. Average the three masses and record them on the percent solid sheet in the front 
of the dipping log. 
3. Use a 3 ml syringe to collect 1.5 – 2.0 ml of BioSpan from the hood. 
4. Dispense BioSpan into weigh dish and repeat steps 1 and 2. 
5. Keep the BioSpan in the oven (at 120˚ F) overnight.   
6. Repeat steps 1 and 2 with the cured BioSpan.  
7. Subtract the weight of the weigh dish from the uncured BioSpan and cured 
BioSpan masses. Divide the weight of the cured BioSpan by the weight of the 
uncured BioSpan and multiply by 100.   If the percent is 20 ± .5%, then 
congratulations, you don’t have to add anything! If the percent is outside the .5% 
range, then you either have to add DMAC or BioSpan.   
 
*(Warning: whenever the vat of BioSpan is open or there is something being dipped, 




wear a pair of latex gloves over your hands and fit nitrile gloves over the black rubber 
gloves inside the hood (Figure A.1).) 
 
Each dip should be recorded the dip in the Dipping Log.  The time recorded for the dip 
should be the time the device is placed on the rotisserie. There should be two hours 
between each dip. 
 
Proximal end – the end of the device with the channels 
Distal end – the end of the device with the cap screwed on (the end w/o channels) 
 





Day 1 – Dipping the Proximal End of the Device (All Pieces Separate) 
1. Heat dipping hood (Figure A.3) up to 120 degrees Fahrenheit with a heat gun or 
another heating element. (It is easiest to set the timer the night before to start the 
heat gun a minimum of two hours at the 7.5 setting before the first dip. The green 
timer clip turns on the timer and the red clip turns the timer off.)  
 







2. Clean mold (A.1) with rubbing alcohol. 
3. Attach the end cap to the center piece of the mold 
4. Screw in gray blocks to the manifolds (side pieces).  
 





5. Attach the aluminum bar to the distal end of the center piece of the mold  
6. Push the long rotisserie wire through the hole in the steel bar and secure it with 
the pin (cylinder with small holes in it).  Attach the other end of the wire to the 
hook on the rotisserie. 
7. Start the rotisserie in order to lift the center mold (keep rotisserie wire taught so 
that it doesn’t get caught in the rotisserie). 
8. Remove the lid from the BioSpan vat and place the vat under the device. 
9. Reverse the rotisserie direction and slowly drop the mold into the BioSpan.   
10. Stop the mold once the BioSpan has reached past the small steel pins (or just past 
the proximal critical area).  
11. Reverse the rotisserie to remove the mold from the BioSpan.  When the mold 
comes out of the BioSpan, immediately start a timer for four minutes as you let 
excess BioSpan drip off.  (It is unnecessary to leave the mold in the BioSpan for a 
 




certain period of time. Once it is dipped, it can be removed immediately 
afterwards.) 
12. Once four minutes are up, insert the longest screw with a nut glued on to the 
proximal end of the centerpiece.  
13. Lower the centerpiece and disconnect the rotisserie wire from the aluminum bar 
and from the rotisserie. 
14. Secure the steel bar and mold to the rotisserie with the pin and clip. Loop the 
hanging wire around the screw at the proximal end (Figure A.5). 
 
15. Dip the proximal side of one manifold (channel end) barely past the critical area. 
16. Hold the manifold (channel side down) over the BioSpan and allow it to drip for 
four minutes.   
 
Figure A.5: Rotisserie setup with the centerpiece and two side manifolds attached 




17. Attach the manifolds to the steel bar using the screws attached to the gray blocks 
and secure them with butterfly nuts. 
18. Check for bubbles after five minutes.  If there are bubbles, use the dentist tools or 
something sharp to pop the bubbles. Do not stop the rotisserie when popping 
bubbles.   
19. Wait two hours. 
20. Remove steel bar from rotisserie and repeat steps 4 – 15 one time.  Remember to 
remove the long screw before dipping the centerpiece again. 
21. Leave device on rotisserie overnight. 
 
Day 2 – Dipping the Proximal End of the Device (All Pieces Assembled) 
1. Stop rotisserie and remove device attached to aluminum bar from the hood. 
2. Unscrew both manifolds from the aluminum bar and remove grey blocks. 
3. Unscrew centerpiece from aluminum bar. 
4. Using a scalpel, remove thin layer of BioSpan on both manifolds and centerpiece 
that cured in the attachment areas. 
5. Unscrew and remove distal cap from centerpiece.  
6. Wipe down all pieces with rubbing alcohol. 
7. Slide both manifolds into the appropriate positions on the centerpiece, followed 
by the distal cap.  Screw together distal cap and centerpiece to complete assembly 
(Figure A.2). (Try to minimize any gaps between the manifolds and the center 
piece. These make demolding difficult.) 




9. Place device back in dipping hood and wait for the hood to reheat to 120 degrees 
Fahrenheit.   
10. Push the long rotisserie wire through the hole in the steel bar and secure it with 
the pin (cylinder with small holes in it).  Attach the other end of the wire to the 
hook on the rotisserie. 
11. Start the rotisserie in order to lift the center mold (keep rotisserie wire taught so 
that it doesn’t get caught in the rotisserie). 
12. Remove the long screw from the proximal end of the centerpiece (if it is 
attached). 
 
13. Remove the lid from the BioSpan vat and place the vat under the device. 
14. Reverse the rotisserie direction and slowly drop the mold into the BioSpan. 
 





15. Lower the device into the BioSpan until it is submerged to a level just past the 
proximal critical area. 
16. Slowly raise the device from the BioSpan.  Once completely removed, stop the 
rotisserie and allow it to drip while hanging for 5 minutes.   
17. Place lid on BioSpan vat and set it aside. 
18. Screw the long screw into the proximal side of the centerpiece. 
19. Lower the device and disconnect the rotisserie wire from the aluminum bar and 
from the rotisserie. 
20. Secure the steel bar and mold to the rotisserie with the pin and clip. Loop the 
hanging wire around the screw at the proximal end (to ensure a level rotation on 
the rotisserie). 
21. Start the rotisserie at the slowest speed. 
22. Check for bubbles after five minutes.  If there are bubbles, use the dentist tools or 
something sharp to pop the bubbles. Do not stop the rotisserie when popping 
bubbles.   
23. Let the device cure on the rotisserie for two hours and then repeat steps 10-21 two 
additional times.  After the third dip, let the device cure on the rotisserie 
overnight. 
 
Day 3 – Dipping the Distal End of the Device 
1. Stop the rotisserie and remove the long screw from the centerpiece.   




3. Fit screws through holes on the cross-hook and secure the cross hook with wing 
nuts on each screw. 
4. Remove the device and aluminum bar from the rotisserie. 
5. Hook rotisserie wire onto the cross-hook.  The other end of the wire should be 
attached to the hook on the rotisserie. 
6. Raise the device up to a level above the vat height. 
7. Remove the aluminum bar while the device is hanging. 
8. Remove the lid from the BioSpan vat and place the vat under the hanging device. 
9. Slowly lower the device using the rotisserie into the BioSpan vat. 
10. Submerge the device in BioSpan to a level just below the proximal critical area. 
11. Raise the device from the BioSpan and allow excess BioSpan to drip off of the 
device for 5 minutes. 
12. Place lid on BioSpan vat and set the vat aside. 
13. Re-screw the aluminum bar into the distal cap of the device while it is still 
hanging. (Make sure to keep pressure on the bar while screwing it in to make sure 
it is tightly secured. It is okay to feel around for the holes with the screws and 
touch the BioSpan at the bottom of the mold since you will be unable to see the 
holes at this point.) 
14. Lower the device and disconnect the rotisserie wire from the aluminum bar and 
from the rotisserie. 
15. Secure the steel bar and mold to the rotisserie with the pin and clip. Loop the 
hanging wire around the cross hook at the proximal end (to ensure a level rotation 




16. Start the rotisserie at the slowest speed. 
17. Check for bubbles after five minutes.  If there are bubbles, use the dentist tools or 
something sharp to pop the bubbles. Do not stop the rotisserie when popping 
bubbles. 
18. Allow the BioSpan to cure while the device is on the rotisserie for 2 hours. 
19. Following 2 hours, repeat steps 4-25 four more times.  On the final (fifth) dip, 
allow the BioSpan to cure while the device is on the rotisserie overnight. 
 
Day 4 – Laying the Bead 
1. Shut off the heat gun.   
2. Remove the device from the dipping hood. 
3. Unscrew all attachments from the device (aluminum bar, short screws, and cross-
hook). 
4. Wipe down the entire device with rubbing alcohol. 
5. Collect a sample of BioSpan in a 3 mL syringe, attach an 18-gauge needle, and 
place in the fume hood. 
6. Using the syringe, lay a thick line of BioSpan (lay the bead) along one proximal 






7. Place the device in the 120 degree Fahrenheit oven located in the fume hood for 2 
hours to allow the BioSpan to cure. 
8. Repeat step 6 on the other proximal critical area and place the device in the 120 
degree Fahrenheit oven located in the fume hood overnight to allow the BioSpan 
to cure. 
 
Day 5 – Water Submersion 
1. Remove the device from the oven.   
2. Completely submerge the device in a bucket of water overnight to remove any 
excess DMAC within the BioSpan. 
 
Day 6 – De-molding 
1. Remove the device from water and dry it off. 
 




2. Cut away the BioSpan from the proximal and distal end faces of the device (both 
on the center piece and on the manifolds). 
3. Carefully peel away the housing from the mold.  Use alcohol as a lubricant to help 
prevent tearing and ripping.  Slide a plastic paint mixer between the mold and the 
housing to help separate both components. 
4. Once the housing is completely separated from the surface of the mold, remove 
the distal end cap from the device. 
5. Slide the centerpiece out of the housing through the proximal end of the housing. 
6. Remove both manifolds from the housing by pulling them through the distal end 
of the housing.  The housing is now completely separate from the mold and the 
dipping process is complete (A.8). 
 
Leak Testing and Patching: Housing 
Leak Testing Housing 
1. Place a distal cap (part of the mold), that is siliconed closed, in the bottom of the 
housing. 
 




2. Use medical tape to tape the housing to the cap. 
3. Fold over the top of the housing and use plastic clamps to clamp shut. 
4. Attach the connectors to the manifolds and zip tie in place. 
5. Fill device with water from the sink.  Ensure there are no air bubbles in the 
device. 
6. Clamp shut the tubing attached to the connectors when the device and connectors 
are completely full of water. 
7. When the device is completely full of water attach a pressure transducer to one of 
the lure locks and ensure the other lure is closed. 
8. Calibrate the transducer using the hand pump (at 0 and 300 mmHg). 
9. Fill the pressure transducer and line with water 
10. Take the pressure using the Biopac system 
11. Check for leaks, if the device is leaking mark the leak then drain the water out of 
the device by releasing the clamps 
12. If the pressure is below 60 mmHg add more water using a 60 cc lure locking 
syringe 
13. Repeat steps 14-16 until the pressure is 60 mmHg 
14. If the device has no leaks at 60 mmHg then drain the water by releasing the 
clamps 
15. Remove all of the tape and attachments 
16. Wipe dry with paper towel 





Patching Housing with Biospan 
1. Wipe down the area to be patched with alcohol and allow it to dry.   
2. Use a syringe to pull 1-2 ml of BioSpan from a jar of 24% BioSpan and place it 
and the device in the oven (at 120˚ F) for 10 minutes to allow it to heat up.   
3. If necessary, place a piece of tape on the underside of the housing to prevent 
BioSpan from seeping through while patching/curing.   
4. Attach a needle to the syringe and use this to apply a bead of BioSpan to the hole 
in the housing.   
5. Hold the housing in place for almost 15 minutes until the BioSpan sets and won’t 
move once you place it into the oven.   
6. Be careful with the BioSpan! If not used properly, the BioSpan will start to eat 
away at the existing BioSpan – so once you place the bead onto the housing, don’t 
wipe it away again!  
7. Leave device in the oven overnight and the device will be ready to leak test the 
next day.   
 
Rolling Fiber Bundles 
 
Making the fiber bundle for the compliant device is a relatively straightforward process. 
One of the most important precautions to take when wrapping the fiber is to make sure 
everything is sterile and stays sterile. Any unnecessary particles in the fiber have the 




is clean and the blue pads are replaced if necessary. A lint roller is helpful to clean these 
off if any loose particles are on top. Wear gloves when wrapping and touching the fiber. 
 
Making the Core for the Fiber Bundle 
1. See Purpose. 
2. From the dimensioned drawing in Figure A.9, sketch the outline of the core on a 
piece of polycarbonate (thickness = 1/16”).  Note that the drawing found in this 
document is not to scale, so the design must be redrawn on the polycarbonate, not 
simply traced. 
 
3. Using the dremel (with the heavy-duty cutoff wheel attachment) located under the 
bench in a toolbox, cut out the core from the sheet of polycarbonate. It is 
 




important to wear safety glasses during this procedure as bits of material may fly 
off. 
4. Remove the backing on the polycarbonate 
5. Use a piece of sandpaper to sand off any rigid marks along the sides of the core. 
The edges of the core should be smooth so they do not tear the fiber when 
wrapping. 
6. After sanding the edges, wash the core off in the sink with water and a little bit of 
rubbing alcohol. 
7. Clean up the polycarbonate fragments and work area. 
 
Wrapping the Fiber 
1. See Purpose. 
2. Obtain a completed core (H bracket) and wash it off with water and rubbing 
alcohol. 
3. Locate a ring stand with a long rod attached to it and then place the white roll of 
fiber on the end of the rod. 
4. Pull out a length of fiber about 16 inches long. 
5. Locate the double-sided tape in one of the drawers and put a piece of this tape on 
one side of the long end of the H bracket. The other side of the tape will be placed 
on the end of the fiber strand you pulled out. 
6. Flip the H bracket over and attach the end with tape on it to the fiber end as close 
as possible to the melted edge of fiber.  Make sure to place the core vertically 




7. Trim off any extra fiber if needed before you start wrapping. 
8. Now you should have the H Bracket attached and laying on top of the fiber. You 
have to wrap the fiber around the core 42 times for the cTAL. You can count 
each complete revolution around the initial point of attachment as 1 wrap, or you 
can count out 84 flips. You already have 1 flip if you have the H bracket attached 
to the fiber correctly. 
9. You must make sure that the fiber is even on both ends when you are wrapping it. 
There are two layers of fiber and they must be kept even when wrapping. One 
layer should not be higher than the other for example. 
10. When wrapping, do not wrap with tension on the fiber. You should pull out a 
strand and flip the bracket over freely. Do not wind the fiber tightly, but also 
make sure the fiber is not loosely wound to the core. 
11. Remember to stay sterile throughout the wrapping procedure. 
12. Fiber bundles should be 3.6 ± 0.1 cm thick when finished. 
 
 




13. Once you have completed the wrapping, locate the Impulse Sealer on the shelf of 
the bench top. It is long and blue. Plug it in and turn the heating knob to 5. 
14. This is used to melt the two layers of fiber into one. It is very easy to use and all 
you have to do is plug it in and turn the heat knob on the right to about 4 or 5. Let 
it heat for about thirty seconds.  
15. Now place the completed fiber bundle on the left of the Sealer so you have 
enough fiber on the right to fold up on the side of the fiber bundle without 
impeding flow through the top of the bundle. If you melt the fiber too far to the 
right, when you fold it up, the tape will be attached on the top side of the bundle, 
ultimately impeding flow through the bundle.  
16. Push the black handle of the Sealer down to melt the fiber for about 5 seconds and 
release. 
17. Pull about 1 inch of fiber through the sealer to melt the fiber in a second place. 
18. You should now have two distinct melt “lines” on the fiber. 
19. Cut closely down the edge of the first melt line closest to the wrapped bundle. 
20. Now you need to attach the end of the fiber to the side of the bundle. Cut a piece 
of double sided tape, put it on the side of the fiber bundle, and fold the end of 
the fiber up, attaching it securely.  
21. Now you have to melt the ends of the fiber bundle using a Hot Plate. It is located 
on the first shelf. Plug it in and turn the heating knob to 5. It takes a couple 
minutes to warm up.  There should be a small, scrap plate of aluminum on top of 




opposed to the Hot Plate itself when melting.  This is solely for the purpose of not 
accruing melted debris on the Hot Plate. 
22. You need to melt the outer 10 layers or so of fiber together. Do not place the end 
of the bundle on the hot plate too long or you will melt too much of the fiber. 
Melt the other side of the fiber bundle. 
23. Once you have melted both ends of the fiber, check for any loose particles on the 
bundle and remove them. Locate a completed housing and carefully insert the 
fiber bundle through the bottom of the cured compliant housing. 
24. Put the completed housing with fiber bundle inserted into a large plastic bag and 
into the box labeled “Complete Housings and Bundles”. 
 
 
Potting: Binding the cTAL fiber bundle and housing 
Preparing Devices for Potting 
1. Fiber bundles should be 3.6 ± 0.1 cm thick.   
2. Insert bundles into housing – try not to pull on fibers, try to keep them aligned.  
3. Make sure the bundles extend a minimum of .75 inches from the critical area on 
each side of the housing.  
4. Trim the housing down on the proximal side until the housing no longer extends 
past the bundle.   




6. Measure out one 6” x 24” piece of saran wrap and wrap around device. Use 
painter’s tape to tape down the border of the saran wrap, keeping 0.75” of the 
device exposed on each end.   
7. Cut a triangle on both the proximal and distal ends of the device, and on the same 
edge. It should be large enough that you can’t see any of the housing when 
looking through the holes in the top of the potting caps.   
Preparing Centrifuge 
1. Wipe down potting caps with alcohol and use paper towel to grease with Grease-
It.  
2. Spray all threaded rods with Grease-It under the hood.   
3. Assemble cages around devices.  Before tightening screws, make sure the device 
is touching neither the top nor the bottom of the potting caps. Insert a micro-
spatula into top and bottom of potting caps to make sure there is sufficient room.  
Also, make sure housing is in potting caps and is not folded back.   
4. Hand tighten screws first, and make sure the potting caps haven’t warped when 
tightening with a wrench.   
5. Take four elbow connectors and two straight connectors and trim them using a 
dremel so that they do not extend past the inner rims of the potting caps and the 
potting tray respectively.   






Preparing Potting Material 
At all times during preparation, keep materials A and B separate! 
1. Prepare cartridges by marking them with appropriate 5, 135, and 145 mL lines 
(see the master for measurements). 
2. Duct tape the bottom (smaller) opening close. 
3. Use 20 oz syringes to pour A and B into their respective cartridges up to the 145 
mL line. 
4. Label each cartridges as A and B. 
5. Cap the remaining open side with the given black cap. 
 




6. Tip the cartridge over when the cap is half way closed and vent the duct taped 
side so that pressure does not build up inside the cartridge. 
7. Snap cartridges A and B together. 
8. Load the cartridges into the gun. 
9. Open the tape again to allow for venting and pump the lever until the material fills 
the cartridge to the 145 mL line.  
a. Make sure there is an equal amount of potting material in each cartridge. 
b. If material spills out of the cartridges, allow the tape to act as a barrier and 
DON’T LET A AND B MIX OR THEY WILL START TO 
SOLIDIFY. 
10. Press the silver lever and pull back on the handle to release the pressure on the 
cartridges. 
11. Take the cartridges out and replace the duct tape on each. 
12. Keep the cartridges in the hood when not using them. 
 
Potting Procedure 






2. Turn on heating element on centrifuge and turn display on centrifuge to 13 
(corresponding to 224 RPM).  Whenever increasing or decreasing speed on 
centrifuge, adjust by increments of three, wait for centrifuge to reach speed and 
then repeat.    
SOMEONE SHOULD BE WATCHING THE CENTRIFUGE AT ALL TIMES.  BE 
READY TO HIT THE EMERGENCY STOP IF SOMETHING GOES WRONG.  
3. Place both cartridges in oven for half an hour with black plungers facing down 
and tape facing up.  
4. Speed centrifuge up to 41 on the display (707 RPM) after 30 minutes.   
5. While speeding up centrifuge, attach the spiral mixing nozzle to the cartridges and 
then the black threaded cap on top. The black cap will not fit all the way, just 
rotate as far as possible.   
 




6. Put cartridges in caulk gun and purge 10 ml of potting material into waste tray. 
7. Once 707 RPM is reached, open cover from hole in the top of the centrifuge and 
inject 130 ml of potting material evenly into the middle of the white tray.  Stop 
with 5 ml of potting material in each cartridge.  Do not allow potting material to 
accumulate past the holes in the side of the tray.   
8. Close cover and allow centrifuge to spin for twelve minutes at 707 RPM.  
9. Purge the last 5 ml into the waste tray.   
10. After twelve minutes are over, decrease speed to 13 on display.  Let centrifuge 
run for 48 minutes.   
11. Decrease speed to 5 on display. Once it reaches 5, hit stop button. Once centrifuge 
has completely stopped rotating, hit both emergency stop buttons. 
12. Turn off heat gun, unplug centrifuge, and allow cooling down for 10-15 minutes. 
13. Plug centrifuge back in and lift hood a few inches.  Let centrifuge vent for an 
hour.   
14. Separate cages from centrifuge and reattach facing the opposite direction.  
15. Prepare potting material and repeat potting procedure on unpotted side.  
 
Cutting: Exposing the ends of the fibers 
After removing the devices from the potting setup, the potted ends must be cut to 
open up and expose the hollow fibers. 
1. Measure ¼’’ in from the inside edge of the potting (on both sides) and mark with 
a sharpie. This is how far in you will cut (1/4’’ of potting must remain on either 





2. Tape back the inlet and outlet manifolds so they are not in the way for cutting. 
3. Place the cTAL in the cutting fixture so that the potted ends are exposed, up to the 
sharpie marks. Tighten down all screws (Figure A.14). 
 
4. Make sharpie marks at the exposed potting – cutting fixture interface. This will be 
your gage as to whether the cTAL is moving in the fixture during cutting. 
 
Figure A.13: Potted cTAL, ready to be cut. Measuring and marking ¼’’ from 
the inside edge of the potting. 
 




5. Use the cutting apparatus at MC3 (Figure A.15). Bring along a sharpie, ruler, hex 
key (for screws), and alcohol. 
 
6. Wear the protective gloves when using the cutting apparatus. 
7. Adjust the blade stop/arm on the cutting bench so that the blade can pass through 
the cTAL without hitting the cutting fixture. 
8. Align the cTAL/cutting fixture with the blade. Squirt alcohol on the blade. 
9. Begin cutting. Take the smallest slices possible. Reapply alcohol to the blade as 
necessary. 
10. IMPORTANT: Make sure the cTAL is not being pulled from the cutting fixture. 
Watch your sharpie marks closely so you don’t cut too far into the potting. 
11. Cut up until the sharpie marks. 
12. Switch sides and repeat. 
13. Remove cTAL from the cutting fixture and repeat with another device. 
 
 




Leak Testing and Patching: Potted and Cut Devices 
Leak Testing Cut Devices: 
1. Attach connectors to manifolds and zip tie in place 
2. Fill device with water from the sink. 
3. When the device is completely full of water attach a pressure transducer to one of 
the lure locks and ensure the other lure is closed. 
4. Fill the pressure transducer and line with water and calibrate the tranducer using 
the hand pump. 
5. Take the pressure using the Biopac system 
6. Check for leaks in both the housing and potting material, if the device is leaking 
mark the leak with a permanent marker, then drain the water out of the device by 
releasing the clamps 
7. If the pressure is below 60 mmHg add more water using a 60 cc lure locking 
syringe 
8. Repeat steps 8 and 10 until the pressure is 60 mmHg 
9. If the device has no leaks at 60 mmHg then drain the water by releasing the 
clamps 
10. Remove all of the connectors  






Patching Cut Devices: Housing 
1. Ensure the housing or potted device is dry before patching. 
2. Using a 3 cc lure lock syringe, draw up 1 mL of BioSpan from the vat in the 
Dipping hood and attach an 18 gauge needle to the syringe.  MAKE SURE THE 
DIPPING HOOD IS CLOSED WHILE THE BIOSPAN VAT IS OPEN.  
3. If necessary, tape down manifolds to keep them out of the way of the patched 
holes. 
4. Place device and syringe in 120 degree farenheight oven for 10 minutes to heat 
up. 
5. Only patch one side of the device at a time to prevent BioSpan from dripping or 
spreading to unwanted areas. 
6. To patch holes, dap a small amount of BioSpan onto the hole.   
7. To patch slits, tape along the slit on the inside of the device.  Then lay a thin line 
of BioSpan along the slit. 
8. Place device and syringe back in oven and let it cure for at lease 3 hours before 
patching the other side and at least 12 hours before leak testing again.  The 
patched side of the device should be facing up. 
 
Patching Cut Devices: Potting 
1. Ensure the device is dry before patching. 
2. Clean out 3, 1 mL syringes with alcohol to remove lubricant. 
3. Draw up 1 mL of potting material Part A and 1 mL of potting material Part B. 




5. Using either the third syringe or a popsicle stick, lightly dab/eject a little bit of 
potting material onto any holes in the potting. 
6. Place weigh dish and device into the 120 degree farenheight oven (patched side 
facing up).  Let the potting material dry for at least 2 hours before patching the 
other side, or overnight before leak testing again. 
 
Attaching Gas Caps and Performing Air Leak Tests 
1. Epoxy connectors in the acrylic gas caps 
2. Fit the gas caps to the cut ends of the cTAL. Use sandpaper and/or the sanding 
attachment on the Dremel to make the caps fit propery. 
3. Apply silicone around the edge of the cut end and then insert into the gas cap. 
4. Press firmly in place 
5. Apply silicone at the gas cap – cTAL edge/interface so that it is completely 
sealed. 
6. After attaching both caps, set aside and allow it to cure for 24 hours. 
 
 




7. Fill a reservoir, large enough to fit the cTAL, with water. 
8. Clamp the inlet and outlet of the cTAL with blue clamps so no air can escape. 
9. Attach tubing to the 1.4’’ connectors on the gas caps 
10. Attach the tubing to air and blow air (lightly) through the device while the device 
is submerged under water. 
11. Watch for air leaks from the gas caps. 
12. If there are any leaks, mark them with a sharpie and then patch them with silicone 
after the outside of the device is dry. 
13. Allow to cure again for 24 hours and repeat gas leak testing. 
14. Repeat until no air leaks remain.   
 
 
